Drug, bio-affecting and body treating compositions inventions 12/06

20060293216 - Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion: The invention provides a pharmaceutical composition comprising a physiologically active agent and a release sustaining or mucoadhesive agent, characterized in that said release sustaining or mucoadhesive agent comprises a chitosan having a FA of from 0.25 to 0.80.... Agent: Sughrue Mion, PLLC

20060293217 - Pharmaceutical formulations for sustained release: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged... Agent: Lahive & Cockfield, LLP

20060293218 - Salicylate therapeutic compound and process for controlled delivery thereof: A therapeutic composition includes a salicylate administering concert with at least one salicylate excretion compound of a glycine salicylate conjugate and a gluconoride salicylate conjugate. A therapeutic composition is provided that has an extended excretion half-life for a salicylate that includes the administration of the salicylate in concert with an... Agent: Gifford, Krass, Groh, Sprinkle & Citkowski, P.c

20060293219 - Methods of treating diabetes mellitus: Methods of treating diabetes mellitus in a patient in need of such treatment include administering an effective amount of an insulin drug to the patient in order to treat diabetes mellitus in the patient. Methods according to the present invention may “activate” the liver, potentially restoring normal glucose homeostasis to... Agent: Moore & Van Allen PLLC

20060293220 - Calcium phosphate nanoclusters and their applications: Artificial particles known as calcium phosphate nanoclusters are disclosed. The particles contain high concentrations of calcium, particularly for use in nutritional products, neutraceuticals, and pharmacological preparations.... Agent: Fleshner & Kim, LLP

20060293222 - Methods of inducing ovulation: The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's... Agent: Howrey LLP

20060293221 - Mucosal repair by tff2 peptides: The present invention relates to the use of trefoil factor 2 (TFF2) peptides and a pharmaceutical composition comprising TFF2 peptides for increasing the viscosity of mucin in mucus layers and the repair of damaged mucus layers in the gastrointestinal tract (mouth, oesophagus, stomach, small and large intestine, colon) the respiratory... Agent: Novo Nordisk, Inc. Patent Department

20060293224 - Conformationally stabilized cell adhesion peptides: Novel synthetic Arg-Gly-Asp containing peptides which have high affinity and specificity for their receptors by virtue of restrictions on their stereochemical conformation. Such restrictions can be provided by cyclization, by inclusion into a constraining conformational structure such as a helix, by providing an additional chemical structure such as an amide... Agent: Mcdermott, Will & Emery

20060293223 - Uses of melanocortin-3 receptor (mc3r) agonist peptides: The present invention provides methods of treating metabolic disorders, including, for example, obesity, diabetes mellitus, cachexia, sarcopenia, and cardiovascular disorders, methods of inducing weight loss and increasing muscle mass in a patient, by administration of MC3R agonist peptides. Furthermore, the present invention provides the use of an MC3R agonist peptide... Agent: Eli Lilly & Company

20060293233 - Compositions and methods for modulating body weight and treating obesity-related disorders: The present invention relates to compositions and methods for regulating body weight, and for treating conditions associated with obesity, particularly, obesity-related diabetes. The present invention is premised on the discovery that body weight can be effectively regulated by modulating the levels and/or activities of two gut hormones, PYY and ghrelin.... Agent: Scully Scott Murphy & Presser, PC

20060293227 - Cosmetic compositions and methods using transforming growth factor-beta mimics: The invention provides methods, compositions, and kits for a variety of cosmetic uses, where the methods, compositions and kits utilize substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Compositions, methods, and kits contain TGF-β mimics.... Agent: Wilson Sonsini Goodrich & Rosati

20060293230 - Expression and secretion of icil-1 receptor antagonist type ii: Novel glycosylated intracellular IL-1 receptor antagonist type II (icIL-1ra-II) is expressed and secreted in mammalian cells transformed with an expression vector where icIL-1ra-II is secreted by expressing icIL-1ra-II fused to the human growth hormone signal peptide. Also disclosed are a pharmaceutical composition containing glycosylated icIL-1ra-Il as an active ingredient and... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20060293225 - Gmg-2 polynucleotides and polypeptides and uses thereof: The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of GMG-2 polypeptide fragment comprising globular domain and all or part of GMG-2 collagen-like region, has been identified that has utility for reducing body mass, for... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20060293235 - Hgf beta chain variants: The invention provides HGF/Met modulators comprising HGF having mutations in regions that affect HGF function, and antagonists that target said regions. The invention further provides methods of identifying, making and using these modulators.... Agent: Genentech, Inc.

20060293240 - Human sef isoforms and methods of using same for cancer diagnosis and gene therapy: A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion... Agent: Martin D. Moynihan Prtsi, Inc.

20060293232 - Hybrid polypeptides with selectable properties: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are... Agent: Arnold & Porter LLP (18528)

20060293238 - Inactivation resistant factor viii: The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. The nucleic acid sequences of the present invention encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. The nucleic acid sequences of the present invention also encode amino acid... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20060293236 - Injectable osteogenic formula and method of using same: Formulations and methods for growing bone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix.... Agent: Mirick, O'connell, Demallie & Lougee

20060293226 - Medicament and use thereof for tumor therapy: The invention relates to a medicament for tumor therapy, containing a first and a second molecule in an effective concentration, the first molecule representing a1) Annexin V or a molecule that is largely similar thereto, or a2) an effective fragment of Annexin V or the molecule that is largely similar... Agent: Fish & Richardson P.C.

20060293231 - Method for enhancing bone formation: This invention provides a method for facilitating bone formation in a subject comprising delivering to a bone formation-requiring site a composition of matter comprising platelet-rich plasma, calcium, a PAR-activating agent and a bone forming material. This invention further provides a method for facilitating bone formation in a subject comprising (a)... Agent: Cooper & Dunham, LLP

20060293241 - Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocaproic acid: The present invention relates to compositions or kits comprising factor VII or a factor VII-related polypeptide and epsilon-aminocaproic acid, and the use thereof for the treatment of bleeding episodes or enhancement of hemostasis.... Agent: Novo Nordisk, Inc. Patent Department

20060293237 - Psiepsilonrack peptide composition and method for protection against tissue damage due to ischemia: A method of reducing damage to cells and tissue caused by an ischemic or hypoxic event is disclosed. The method includes administering to the cell or tissue, either in vivo or ex vivo, ψεRACK peptide. The peptide can be administered before, during or after the ischemic or hypoxic event.... Agent: Perkins Coie LLP

20060293229 - Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor: Site-specific isotopically-labeled valine, leucine, and isoleucine and biosynthetic precursors for these amino acids are provided. The amino acids are labeled with 13C or 14C at the methyl group carbon atom(s) most remote from the carboxyl group. Also disclosed are the biochemical precursors of these labeled amino acids, 2-keto-4-(nC) butyric acid... Agent: Wood, Phillips, Katz, Clark & Mortimer

20060293228 - Therapeutic compositions and methods using transforming growth factor-beta mimics: The invention provides methods, compositions, and kits for treating a variety of conditions using substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Conditions include skin conditions, wounds, and the need for soft tissue augmentation. Compositions that may be used to treat such conditions contain a... Agent: Wilson Sonsini Goodrich & Rosati

20060293234 - Therapeutic peptides for the treatment of metastatic cancer: Interaction between MUC1 and β-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUC1. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.... Agent: Banner & Witcoff

20060293239 - Treatment and diagnosis of insulin-resistant states: Dickkopf-5 (Dkk-5) protein is administered in effective amounts to treat disorders involving insulin resistance, such as non-insulin-dependent diabetes mellitus (NIDDM) or obesity. Also provided is a method of diagnosing insulin resistance and related disorders using Dkk-5 as a measure, and kits for diagnosis and treatment, as well as hybridomas producing... Agent: Merchant & Gould PC

20060293242 - Transporting of taxoid derivatives through the blood brain barrier: Taxoid derivatives are used in the treatment of cancers, particular cancers of the central nervous system, such as brain cancers. Taxoid derivatives are transported across the blood/brain barrier (BBB). A compound is provided which consists of at least one taxoid derivative bound to at least one vector peptide capable of... Agent: Bachman & Lapointe, P.C.

20060293244 - Anti-inflammatory compounds and uses thereof: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell.... Agent: Lahive & Cockfield, LLP

20060293243 - Stable, buffered, pharmaceutical compositions including motilin-like peptides: Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization.... Agent: Baxter Healthcare Corporation

20060293246 - Methods of modulating beta cell function: Methods of modulating pancreatic function by modulating MCH signaling in a β cell.... Agent: Fish & Richardson PC

20060293245 - P21 derived peptides and uses thereof: The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving... Agent: Lahive & Cockfield, LLP

20060293247 - Trh-like peptide derivatives as inhibitors of the trh-degrading ectoenzyme: e

20060293248 - Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the... Agent: Sonnenschein Nath & Rosenthal LLP For Paula Evans

20060293250 - Crystalline sugar compositions and method of making: Described are novel crystalline pivaloyl furanoses and methods of crystallizing the pivaloyl furanoses. These compounds are useful as intermediates in the synthesis of compounds such as the deoxyjirimycins and nojirimycins and are particularly useful as intermediates for production on a multi-kg scale. Particular crystalline compounds include 1,2,3,6-tetrapivaloyl-α-D-galactofuranose, 1,2,3,6-tetrapivaloyl-α-L-altrofuranose, and 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-α-D-galactofuranose.... Agent: Baker & Botts

20060293253 - Indole compounds useful for the treatment of cancer: The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20060293252 - Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof: e

20060293249 - Porphyrin derivatives:

20060293251 - Substituted indazole-o-glucosides: Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20060293254 - Podophyllotoxin: The invention relates to podophyllotoxins, uses thereof and methods of their production.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20060293255 - Method for regulating nutrient absorption with ginsenosides: There is provided a method for regulating the absorption of a nutrient in a subject, including administering to the subject an effective amount of a ginsenoside compound purified from Panax notoginseng for modulating transportation of the nutrient across gut cells of the subject.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20060293259 - Compositions and methods of use of derivatized flavanols: The invention relates to compositions containing derivatized flavanols such as methylated flavanols, and methods of use thereof for prophylactic or therapeutic treatment of a human or a veterinary animal for example as anti-platelet agents.... Agent: Nada Jain, P.C.

20060293258 - Method and composition to treat skin ulcers: The invention is directed to a method for treating ulcers, including ulcers of the lower leg, by topical plus oral administration of proanthocyanidins to a patient.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. The Chrysler Center

20060293257 - Methods for the treatment of scar tissue: A topical composition and method for the reduction of scar tissue and/or improving the appearance of scar tissue after it has formed. The topical composition includes one or more flavonoids formulated in a pharmaceutically acceptable topical carrier. The method includes the step of topically applying a composition including one or... Agent: Knoble, Yoshida & Dunleavy

20060293256 - Remedy or preventive for kidney disease and method of diagnosing kidney disease: A novel agent for therapy and/or prevention of kidney diseases as well as a diagnostic method (detection method) of kidney diseases is disclosed. The agent for therapy and/or prevention of kidney diseases comprises as an effective ingredient a substance which inhibits casein kinase 2. The diagnostic method of kidney diseases... Agent: Birch Stewart Kolasch & Birch

20060293260 - Useful high load concentrate compositions for control of ecto-and endo-parasites: High load concentrate compositions comprising metaflumizone, a substantially water-insoluble anti-parasitic macrolide compound,such as moxidectin, an optional bridging agent, a surfactant, and a suitable carrier solvent are prepared. These compositions may be topically administered to animals, and are useful for preventing or treating ectoparasitic infestations in warm-blooded animals for prolonged periods... Agent: Wyeth Patent Law Group

20060293261 - Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli: For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060293268 - Antisense antiviral compounds and methods for treating foot and mouth disease: An antiviral antisense composition and method for treating foot-and-mouth disease virus (FMDV) in veterinary animals is disclosed. The composition contains an antisense compound that has a sequence effective to target at least 12 contiguous bases of an FMDV RNA sequence within a region of the positive-strand genomic RNA defined by... Agent: Perkins Coie LLP

20060293269 - Antisense modulation of superoxide dismutase 1, soluble expression: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of... Agent: Knobbe, Martens, Olson & Bear, LLP

20060293267 - Dual functional oligonucleotides for use as anti-viral agents: The present invention is based, in part, on the discovery that endogenous mRNAs, such as viral miRNAs, can be recruited for translational repression of target mRNAs, such as viral target mRNAs. The RNA-silencing agents and the methods described herein, thereby provide a means of treating viral infections, of treating diseases... Agent: Lahive & Cockfield, LLP

20060293262 - Inhibition of gene expression using rna interfering agents: The present invention is based, at least in part, on the discovery of compositions and methods for the treatment and prevention of infectious diseases or disorders, e.g., HIV infection, AIDS, and AIDS-related diseases. In particular, the present invention pertains to methods of modulating cellular gene expression or protein activity, e.g.,... Agent: David S Resnick Nixon Peabody

20060293270 - Methods and compositions for treating ocular disorders: This invention relates to methods of treating ocular disease. The method of the invention is directed to the administration of an anti-vascular endothelial growth factor (anti-VEGF) compound to treat such disease.... Agent: (osi) Eyetech, Inc.

20060293265 - Methods involving aldose reductase inhibitors: Embodiments of the invention include methods and compositions involving aldose reductase inhibitors for the treatment of sepsis and autoimmune diseases, including Type I diabetes and rheumatoid arthritis. The invention also pertains to preventing the loss of cardiac muscle contractibility.... Agent: Fulbright & Jaworski L.L.P.

20060293266 - Phosphodiesterase 4d in the ryanodine receptor complex protects against heart failure: The present invention provides compositions useful for treating and preventing ryanodine receptor associated disorders comprising a PDE-associated agent and a pharmaceutically acceptable carrier. The present invention also provides methods for treating or preventing ryanodine receptor associated disorders including cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and... Agent: Thelen Reid & Priest LLP Leslie G. Restaino

20060293263 - Preparation for preventing contact of pathogenic matter with living organism: Intermolecular mutual recognition between pathogenic matter, such as allergen group or disease-causing microbe, capable of functioning at the attachment thereof to living organism and a living organism is inhibited by the use of pectins or nucleic acids.... Agent: Young & Thompson

20060293271 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060293272 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060293264 - Stat3 decoy oligonucleotides and uses therefor: A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating... Agent: Jesse A. Hirshman, Esq.

20060293273 - Methods, compositions, and formulations for preventing or reducing adverse effects in a patient: The present invention provides methods, compositions, formulations, and kits related to acadesine, or a prodrug, analog, or salt thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a... Agent: Wilson Sonsini Goodrich & Rosati

20060293274 - N²-quinoline or isoquinoline substituted purine derivatives: wherein W represents a hydrogen, an optionally substituted C1-6 alkyl, an optionally substituted C3-6 cycloalkyl, or an optionally substituted C1-6 haloalkyl, Y represents a hydrogen, or a saccharide, Q represents a quinoline or isoquinoline. Also disclosed are a pharmaceutical compositions comprising the same, methods for treating cancer using the same,... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20060293275 - Hgf production accelerator containing heparin-like oligosaccharide: The present invention aims to provide an agent for promoting HGF production comprising, as an effective ingredient, a disaccharide comprised of an uronic acid residue (wherein an uronic acid means an iduronic acid or a glucuronic acid, and has the same meaning hereinafter) and a glucosamine residue that are connected... Agent: Wenderoth, Lind & Ponack, L.L.P.

20060293277 - Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making for making them: The present invention provides for compositions of hyaluronic acid cross-linked with at least one other hydrophobic polymer to form a copolymer gel. The preferred composition is a formulation containing hyaluronic acid or its derivatives and a silicone base polymer with a functional group capable of reacting with the preferred cross-linker.... Agent: Sheldon Palmer C/o Galvin & Palmer

20060293278 - Novel therapeutic uses of glucan: A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060293276 - Use of lipid conjugates in the treatment of disease: This invention provides a method of preventing asthma, allergic rhinitis, or chronic obstructive pulmonary disease in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20060293279 - Administration of enoxaparin sodium to patients with severe renal impairment: Methods having novel enoxaparin sodium dosing regimens for patients with severe renal impairment are disclosed. The methods may be used for one or more of preventing thrombotic episodes, treating thrombotic episodes, preventing postoperative venous thrombosis, controlling thrombosis and/or decreasing blood hypercoagulation and/or hemorrhaging risks, treating unstable angina, and treating non-Q-wave... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060293280 - 1,3-oxathiolane-2-thione compounds: wherein R1 and R2 are the same or different, each of which denotes a straight-chain or branched alkoxy residue with 1 to 6 carbon atoms or an aryloxy or aralkyloxy residue, R3 is different or the same as R1 or R2 or an aliphatic residue, an amino residue, a halogen... Agent: Henkel Corporation

20060293281 - N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: e

20060293282 - Substituted aminoalkanephosphonic acids: The present invention relates the use of substituted aminoalkanephosphonic acids in treating neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders.... Agent: Novartis Corporate Intellectual Property

20060293284 - Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same: The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof.... Agent: Birch Stewart Kolasch & Birch

20060293283 - Prodrugs of a2b adenosine receptor antagonists: Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states.... Agent: Brian Lewis Cv Therapeutics, Inc.

20060293285 - Aryl phosphate derivatives of d4t: Specific aryl phosphate nucleoside derivatives show activity against HIV without undesirable levels of cytotoxic activity. In particular, these derivatives are potent inhibitors of HIV reverse transcriptase. Examples of aryl phosphate nucleoside derivatives include aryl phosphate derivatives of d4T having one or more substituents on the aryl group, and wherein the... Agent: Merchant & Gould PC

20060293286 - Resistant-repellent retroviral protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.... Agent: Proskauer Rose LLP

20060293287 - Storage stable formulation and a process for its preparation: The present invention is directed to a storage stable insecticidal composition comprising one or more Chloronicotynyle compound, in an amount ranging from 0.1 to 5% by weight of the composition, one or more compounds falling within the group of Organophosphorus compounds in an amount ranging from 30 to 75% by... Agent: Jones, Tullar & Cooper, P.C.

20060293288 - Use of resolvins to treat gastrointestinal diseases: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of... Agent: Dorsey & Whitney LLP Intellectual Property Department

20060293289 - Compounds capable of activating cholinergic receptors: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.... Agent: Womble Carlyle Sandridge & Rice, PLLC

20060293290 - Method for the treatment of acne: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.... Agent: Maryellen Feehery

20060293291 - 2-propylidene-19-nor-vitamin d compounds: 2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone... Agent: Andrus, Sceales, Starke & Sawall, LLP

20060293292 - Methods of using acyl hydrazones as seh inhibitors: Disclosed are hydrazine compounds useful as soluble epoxide hydrolase (sEH) inhibitors for treating cardiovascular diseases.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20060293294 - Method for treatment or prevention of androgen deficiency: This invention relates to a method for the treatment or prevention of androgen deficiency in a male individual by administering to the individual an effective amount of a selective estrogen receptor modulator, or an isomer, isomer mixture, metabolite or a pharmaceutically acceptable salt thereof. Furthermore, the invention concerns methods for... Agent: Fitzpatrick Cella Harper & Scinto

20060293295 - Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6s)-tetrahydrofolate: The present invention relates to a pharmaceutical composition which may comprise progestogens, preferably drospirenone, estrogens, preferably ethinylestradiol and 5-methyl-(6S)-tetrahydrofolate, which may be employed as oral contraceptive and moreover prevents disorders caused by folate deficiency in the consumers, in particular cardiovascular disorders and, after conception of the embryo, congenital malformations caused... Agent: Frommer Lawrence & Haug

20060293293 - Salmeterol and ciclesonide combination: The invention relates to pharmaceutical compositions containing combinations of salmeterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.... Agent: Nath & Associates PLLC

20060293296 - Process for the preparation of cefpodoxime procetil: A process for the preparation of cefpodoxime proxetil of high purity conforming to pharmacopoeial specifications.... Agent: Cooper & Dunham, LLP

20060293298 - Compounds: p

20060293301 - Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as premenstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity,... Agent: Woodcock Washburn LLP

20060293300 - New substituted thiophene carboxamides, process for their preparation and their use as medicaments: e

20060293299 - Substituted 3-alkyl and 3-alkenyl azetidine derivatives: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20060293297 - Cyanofluoropyrrolidine derviative: R3 represents a group represented by the formula: —N(R4)COR5, —N(R4)SO2R5, —NR4R6, —SO2R5, —SO2NR4R5, —OCONR4R5, —CH═CH—R7 or —C≡C—R7, or represents a heteroaryl group selected from a heteroaryl group which contains at least one oxygen and/or sulfur atom and which may further contain a nitrogen atom, and a 6-membered nitrogen-containing aromatic ring... Agent: Sughrue Mion, PLLC

20060293303 - Antiprotozoal imidazopyridine compounds: Compounds described by the Formula (I) or (II): or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination... Agent: Merck And Co., Inc

20060293302 - Imidazopyridine-derivatives as inducible no-synthase inhibitors: m

20060293304 - Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein: A process is provided for preparing triazole substituted azaindoleoxoacetic piperazine derivative. Novel intermediates produced in the above process, and novel N-1 and amorphous forms of a 1,2,3-triazole substituted azaindoloxoacetic piperazine derivatives and processes for producing such novel forms are also provided.... Agent: Louis J. Wille Bristol-myers Squibb Company

20060293305 - Preparation of hymenialdisine derivatives and use thereof: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α). The chemically-synthesized indoloazepines of the invention also inhibit... Agent: Mcleod & Moyne, P.C.

20060293306 - Viral polymerase inhibitors: e

20060293310 - Derivatives of 1-piperazine-and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme: Wherein m, R1 and R2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20060293309 - Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors: The instant invention features compounds, for example, 5-HT3 receptor antagonists, having a peripherally restricted mode of action such that the compounds affect 5-HT3 receptors of the peripheral nervous system with diminished or reduced effects in the central nervous system. The compounds are particularly useful in treating disorders or conditions ameliorated... Agent: Lahive & Cockfield, LLP

20060293307 - Oxazolidinone derivatives as antimicrobials: The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including... Agent: Ranbaxy Inc.

20060293308 - Pyridyl derivatives and their use as therapeutic agents: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): wherein W, V, x, y, R1, R2, R3, R4, R5, R6, R7, R7a, R8, R8a, R9, R9a, R10... Agent: Osha Liang L.L.P.

20060293311 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.... Agent: Foley & Lardner LLP

20060293312 - Method of improved diuresis in individuals with impaired renal function: Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal comprising the step of administering a therapeutically effective amount of KW-3902, or... Agent: Knobbe Martens Olson & Bear LLP

20060293313 - New phenylpiperazines: s

20060293314 - 4- piridinylmethylsulphonamide derivatives as fungicidal plant protein agents: X is phenyl, naphthyl or a five- or six-membered saturated, or partially unsaturated or aromatic heterocycle which is attached via a carbon atom and contains one to four heteroatoms from the group consisting of O, N and S, where X may be substituted according to the description; Processes for preparing... Agent: Birch Stewart Kolasch & Birch

20060293315 - Intermediates of novel heterocyclic compounds having antibacterial activity and process for their preparation: i

20060293316 - Hexahydro-pyrrolo-isoquinoline compounds: Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20060293317 - Use of non-steroidal progesterone receptor modulators: r

20060293318 - Stereospecifically substituted benzo[1,3]dioxolyl derivatives:

20060293320 - Heteroaryl derivatives for treating viruses: Disclosed are compounds, compositions, and methods for treating Flaviviridae family virus infections.... Agent: Foley & Lardner LLP

20060293319 - Oxindole derivatives: s

20060293321 - 2-heterosubstituted 3-aryl-4h-1-benzopyran-4-ones as novel therapeutics in breast cancer: The present invention provides 2-heterosubstituted 3-aryl-4H-benzopyran-4-one compounds for the treatment of cancers, namely breast cancer. This invention further provides a method of synthesis of 2-(alkylthio)isoflavones that can be carried out at ambient conditions. This invention further provides a method of synthesis of the 2-heterosubstituted 3-aryl-4H-benzopyran-4-one from a 2-(alkylthio)isoflavone. The invention... Agent: Calfee Halter & Griswold, LLP

20060293322 - Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders: The present invention relates to a compound of Formula (I) and its use in treating hyper-proliferative disorders.... Agent: Jeffrey M. Greenman

20060293323 - Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies: Administration of an irreversible tyrosine kinase inhibitor such as CI-1033 in combination with one or more other antineoplastic agent(s), or ionizing radiation is synergistic for treating cancer.... Agent: Pfizer Inc

20060293324 - Pyrimidine compounds: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the... Agent: Fish & Richardson PC

20060293325 - Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments: where Z is an amine, alcohol, or thiol-containing group, and Y is an alkyl-containing amine. Methods of producing such compounds and using them to treat patients with diabetes and obesity are also disclosed. The present invention also relates to treating such conditions with GADPH inhibitors and screening compounds useful for... Agent: Nixon Peabody LLP - Patent Group

20060293326 - 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases: The invention relates to 2-Heteroaryl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases. The present invention relates to compounds of the general formula (I) in which R1 denotes 5- to 10-membered heteroaryl, which is optionally substituted by... Agent: Jeffrey M. Greenman

20060293327 - Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060293328 - Linear dicationic terphenyls and their aza analogues as antiparasitic agents: Novel dicationic terphenyl compounds and their aza analogues. Methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues. Processes for synthesizing novel dicationic terphenyl compounds and their aza analogues.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20060293329 - Substituted enaminones, their derivatives and uses thereof: The present invention is related substituted enaminones represented by a compound of Formula I that are novel allosteric modulators of α7 nAChRs. The invention also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of... Agent: Heller Ehrman LLP

20060293330 - Hiv replication inhibiting purine derivatives: e

20060293334 - Nitrogen-containing heteroaryl compounds having inhibitory activity against hiv integrase:

20060293331 - Process of synthesizing tadalafil: The present invention provides tadalafil of high purity and processes of making such tadalafil by cyclization of TDCl in a solution.... Agent: Kenyon & Kenyon LLP

20060293332 - Sulfonylquinoxalone derivatives and related compounds as bradykinin antagonists: Disclosed are sulfonylquinoxalone acetamide derivatives useful as bradykinin antagonists.... Agent: Foley & Lardner LLP

20060293333 - Therapeutic amides: wherein A, X, Y, and Z are as defined in the specification. The compounds are effective anti-tumor agents. The invention also provides pharmaceutical compositions comprising a compound of the above formula or a salt thereof, intermediates useful for preparing a compound of the above formula, and therapeutic methods comprising administering... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20060293335 - Riboflavin derivative and its manufacture and uses: The invention discloses riboflavin derivatives, and a process of preparing the same, and their applications. The w/o suspending preparation of the riboflavin derivatives has high stability, and the effects could last for 3 months after intramuscular injection at dose of 150 mg. This invention increases significantly the bioavailability of riboflavin... Agent: Ladas & Parry LLP

20060293336 - C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions: e

20060293337 - P2x7 receptor antagonists and their use: The invention provides compounds of formula (IA), processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.... Agent: Fish & Richardson P.C.

20060293338 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060293340 - 2-aminopyrimidine derivatives as raf kinase inhibitors: This application discloses compounds that inhibit Raf kinase having the formula (I), wherein R1 is a phenyl radical or a heteroaryl radical; and R2 is a phenyl radical; or an N-oxide or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of proliferative diseases, such as cancer.... Agent: Novartis Corporate Intellectual Property

20060293341 - Alkyl sulfonamide derivatives: This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20060293339 - Biaryl substituted 6-membered heterocycles as sodium channel blockers: Biaryl substituted pyridine, pyrimidine and pyrazine compounds are sodium channel blockers useful for the treatment of pain. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with,... Agent: Merck And Co., Inc

20060293343 - Pyrimidine derivatives: a

20060293344 - Therapeutic compounds:

20060293342 - Tie-2 modulators and methods of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20060293345 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.... Agent: Hoffmann & Baron, LLP

20060293346 - Fungicidal mixtures: e

20060293347 - Pharmaceutically active compounds: wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of,... Agent: Pfizer Inc.

20060293348 - Novel compounds: Novel substituted 2, 4, 8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060293349 - 5-chloro-4-alkyl-3,4-dihydro-quinazolin-2-ylamine derivatives: v

20060293351 - Promotion of wound healing: A promotor of wound healing and an inhibitor of formation of a urethral stricture, particularly following surgical intervention or infection in the area. Specifically, the most preferred compound of the present invention, Halofuginone, can be used to prevent collagen deposition from occurring within the lumen of the urethra after such... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20060293350 - 8-alkoxy or cycloalkoxy-4-methyl-3,4-dihydro-quinazolin-2-ylamines: n are as described in the specification and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I can be used for the treatment of 5-HT5A receptor antagonists related diseases, which include depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory... Agent: Hoffmann-la Roche Inc. Patent Law Department

20060293353 - Matrix metalloproteinase inhibitors: R14 and R15 each independently represent H, C1-6 alkyl, C1-4 alkylaryl or C1-4 alkylheteroaryl or together with the functionality to which they are attached R14 and R15 form a heterocyclic or fused heterocyclic group; and physiologically functional derivatives thereof, corresponding processes for preparation, pharmaceutical formulations containing them and their use... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060293352 - Phenoxiacetic acid derivatives: The invention relates to certain 2-substituted phenoxyacetic acid derivatives of formula (I), in which the variables are as defined in the claims, useful in the treatment of diseases or conditions in which modulation of the CRTh2 receptor is beneficial, such as asthma and rhinitis.... Agent: Fish & Richardson P.C.

20060293355 - Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s)-3, 5-dihydroxyhept-6-enoicacid] calcium salt: Two polymorphic forms of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid]calcium salt, processes for making them and their use as HMG Co-A reductase inhibitors are described.... Agent: Morgan Lewis & Bockius LLP

20060293354 - Pyrimidine derivatives and their use as cb2 modulators: The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20060293356 - Methods for treating smooth muscle contractions using trospium: Methods are disclosed using trospium, an antimuscarinic smooth muscle relaxant, for the treatment of smooth muscle disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.... Agent: Nields & Lemack

20060293357 - Intermediates for synthesis of vinblastine, process for preparation of the intermediates and process for synthesis of vinblastines: A method for synthesis of the compound of general formula A utilizing radical ring forming reaction of thioanilides and using the compound of general formula B as the starting material, synthesizing thioanilide of general formula C by the reaction with compound 1 and the formation of a 11-membered ring by... Agent: Hahn & Voight PLLC

20060293358 - Tyrosine kinase inhibitors: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20060293359 - Methods and compositions for the treatment of diabetes: Disclosed is a method for treating symptoms of diabetes using an agonist of the α2B and/or α2C adrenergic receptor subtypes that lacks (a) significant α2A adrenergic receptor activity or (b) significant α1A adrenergic receptor activity, or that lacks both (a) and (b).... Agent: Allergan, Inc.

20060293360 - 4-(2-phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors: The invention provides compounds represented by the general formula (I) wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.... Agent: Darby & Darby P.C.

20060293361 - Compounds: e

20060293362 - Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them: The invention relates to nitro-substituted 7-hydroxyindoles, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active compounds for treating diseases which can be influenced by using the compounds according to the invention... Agent: Fulbright & Jaworski, LLP

20060293363 - Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles: Improved processes for preparing substituted 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazoles are disclosed.... Agent: Kenyon & Kenyon LLP

20060293364 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: p

20060293366 - Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors: inhibit the formation of the β-amyloid peptide (β-A4) and are, therefore, useful in the treatment of pathologies in which a β-amyloid peptide (β-A4) formation inhibitor provides a therapeutic benefit. Particular such pathologies are senile dementia, Alzheimer's disease, Down's syndrome, Parkinson's disease, amyloid angiopathy, cerebrovascular disorders, frontotemporal dementias and Pick's disease,... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20060293365 - Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics: h

20060293367 - Amorphous n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide: An amorphous drug, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060293368 - Amorphous n-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride: Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride, processes for making it, compositions containing it and methods of treatment of diseases using it are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060293369 - Fungicidal composition comprising a pyridylmethylbenzamide derivative and chlorothalonil: A fungicidal composition comprising at least a pyridylmethylbenzamide derivative of general formula (I) and a chloronitrile derivative which is chlorothalonil; in a compound (I)/chlorothalonil weight ratio of from 0.005 to 1. Method for preventively or curatively combating the phytopathogenic fungi of crops by using this composition.... Agent: Ostrolenk Faber Gerb & Soffen

20060293370 - Sulfonamide compounds and uses thereof: Compounds that modulate GHS-R are described, for examples compounds formula (I)... Agent: Fish & Richardson PC

20060293371 - Prodrug and process for producing the same: m

20060293372 - Beta-sheet mimetics and methods relating to the use thereof: β-sheet mimetics and methods relating to the same are disclosed. The β-sheet mimetics have utility as protease and kinase inhibitors, as well as inhibitors of transcription factors and protein-protein binding interactions. Methods of the invention include administration of a β-sheet mimetic, or use of the same for the manufacture of... Agent: Seed Intellectual Property Law Group PLLC

20060293373 - Gamma-secretase inhibitors: x

20060293374 - Substituted isothiazolones: and pharmaceutically acceptable forms thereof useful as inhibitors of cPLA2 and a method for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, disorder or condition using a compound of Formula (I) and, more particularly, for preventing, treating or ameliorating a cPLA2 mediated inflammatory related disease, disorder or condition... Agent: Philip S. Johnson Johnson & Johnson

20060293377 - Amorphous and polymorphic forms of telmisartan sodium: Provided is the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of... Agent: Kenyon & Kenyon LLP

20060293376 - Benzopyran derivatives substituted with a benzimidazole derviative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them: The present invention relates to benzopyran derivatives substituted with a benzimidazole derivative, or pharmaceutically acceptable salts thereof, a preparation method of the same and pharmarceutical compositions containing them. Benzopyran derivatives substituted with a benzimidazole derivative, represented in Formula (1), have the function of protecting heart from ischemia-reperfusion without side effect... Agent: Lucas & Mercanti, LLP

20060293375 - Crystal of benzimidazole derivative and process for producing the same: Various crystal forms of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid from a solvent, and a process for production thereof are provided.... Agent: Sughrue Mion, PLLC

20060293378 - Method of lowering intraocular pressure: A method of lowering intraocular pressure and/or treating glaucoma comprises administering to a patient a therapeutically effective amount of a fused pyrrolocarbazole derivative, or a pharmaceutically acceptable salt or prodrug thereof.... Agent: Bausch & Lomb Incorporated

20060293379 - Quaternary salt ccr2 antagonists: m

20060293380 - Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20060293381 - Fungicidal effect by regulating signal transduction pathways: The present invention concerns methods of treating fungal infections and methods of screening compounds for activity in treating fungal infections. Methods of the invention include using an active compound such as fludioxonil to treat a Cryptococcus neoformans infection. Also included are methods and pharmaceutical compositions useful for treating fungal infections... Agent: Myers Bigel Sibley & Sajovec

20060293382 - Stable warfarin sodium liquid formulation and method of making same: A stable liquid composition comprising warfarin sodium, glycerin, an alcohol such as ethanol, and a pH buffer such as a phosphate buffer providing a pH above 7 is provided. The stability of the composition is characterized by the amount of warfarin sodium in the composition degraded after 1 month at... Agent: Winston & Strawn LLP Patent Department

20060293383 - Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain: wherein phenyl is substituted at X with one to five halogen atoms independently selected from the group consisting of fluorine, chlorine, bromine and iodine; and; R1 and R2 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with phenyl (wherein phenyl... Agent: Philip S. Johnson Johnson & Johnson

20060293384 - Isethionyl nitrates and compounds thereof: in which the cation M is selected from the group consisting of: hydrogen, alkali metal cations, alkaline earth metal cations, Group III metal cations, transition metal cations, ammonium ions (including organic-substituted ammonium cations), including mixtures of any two or more of the foregoing; R1 and R2 are each independently selected... Agent: Christopher J. Whewell Western Patent Group

20060293385 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, sulfonate and sulfonamide functional diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.... Agent: Eli Lilly & Company

20060293386 - Method for treating cancer: It is an object of the present invention to provide a method for cancer treatment to suppress cancer, specifically hepato cellular carcinoma. There is discovered effective suppression of the progression of hepatocellular carcinoma with gabexate mesilate, a non-anticancer drug that has not been used as an anticancer drug. Gabexate mesilate... Agent: Jordan And Hamburg LLP

20060293387 - Agent for lowering neutral fat concentration in blood: An agent for lowering neutral fat concentration in blood and a therapeutic agent for a disease to which neutral fat in blood is related, the agent containing astaxanthin and/or esters thereof. The agent for lowering neutral fat concentration in blood according to the present invention is useful for treating various... Agent: Le-nhung Mcleland

20060293388 - Pomolic acid, its isomers, derivatives and their uses, pharmaceutical composition, method to prepare the pharmaceutical composition and method for treating multidrug resistant tumours: The present invention describes the use of pomolic acid, its derivatives and pharmaceutical preparations derived from them as anti-neoplasic agents in the treatment of multidrug resistant tumors. In relation to other drugs that present anti-MDR activity, these substances do not require the concomitant use of reversers to exert their anti-MDR... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20060293389 - Process for producing injectable gabapentin compositions: Injectable compositions containing gabapentin and processes for preparing sterile injectable compositions containing gabapentin are discussed. The process includes subjecting the compositions to heat. Heating results in increased production of gabapentin lactam, which has previously been shown to be toxic. Surprisingly, heated injectable compositions containing gabapentin are found to be non-toxic... Agent: Medtronic, Inc.

20060293390 - Diflunisal for the treatment of cancer: The invention is directed to the use of Diflunisal for the preparation of a medicament for the treatment of cancer, wherein the medicament is adapted for administration so that a molecular ratio of 4:1 to 6:1 of interstitial Diflunisal to interstitial albumin is provided.... Agent: Reed Smith LLP

20060293391 - Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases: The invention describes the use of deoxyspergualin (DSG) or an analogue thereof for the preparation of a medicament for the treatment of and/or prophylaxis against hyperreactive inflammatory diseases and autoimmune diseases, wherein the treatment is performed in cycles.... Agent: Frommer Lawrence & Haug

20060293392 - Benzamide derivatives and uses related thereto: e

20060293393 - Iptakalim hydrochloride for decreasing nicotine use: A method for decreasing nicotine and other substance use in humans is disclosed. Iptakalim hydrochloride (IPT) is a novel nicotine acetylcholine receptor (nAChR) blocker. According to the disclosed method, IPT is used to block human α4β2-nAChR function. Specifically, IPT exhibits a selective blockade of α4 subunit-containing human nAChR subtypes. According... Agent: Jennings, Strouss & Salmon, P.L.C

20060293394 - Combretastatin analogs with tubulin binding activity: Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060293395 - Methods for treating a mammal before, during and after cardiac arrest: Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060287220 - Water soluble paclitaxel prodrugs: Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include... Agent: Foley And Lardner LLP Suite 500

20060287221 - Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia: Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.... Agent: Novo Nordisk, Inc. Patent Department

20060287222 - Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing: A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287224 - Glycopegylated erythropoietin formulations: The present invention provides conjugates between erythropoietin and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified... Agent: Morgan, Lewis & Bockius LLP (sf)

20060287223 - Remodeling and glycoconjugation of peptides: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20060287225 - Integrin inhibitors for the treatment of eye diseases: Methods and compositions for prophylaxis and/or treatment of diseases of the eye using antagonists of the integin receptors αvβ3 and/or αvβ5. The compositions can be nanoparticles and are administered to the eye by injection into the vitreous body of the eye.... Agent: Millen, White, Zelano & Branigan, P.C.

20060287232 - Antimicrobial peptides: Artificial antimicrobial peptides are obtained by alterations in alpha helical portions of a known antimicrobial protein, granulysin. The peptides obtained have significantly improved antimicrobial activity and lack the ability to lyse mammalian cells, which may be toxic to a host. The peptides may be designed according to certain guidelines, and... Agent: Peters Verny Jones & Schmitt, L.L.P.

20060287226 - Characterization of a membrane estrogen receptor: The present invention discloses the identification of a novel membrane associated estrogen receptor, termed mER. The membrane associated receptor is involved in rapid signal transduction. Amino acid sequences, nucleic acid sequences, vectors, and host cells are also discussed. Additionally, methods of detecting agonists and antagonists for the receptor are disclosed... Agent: Darby & Darby P.C.

20060287230 - Compositions which can be used for regulating the activity of parkin: The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating,... Agent: Wiley, Rein & Fielding, LLP Attn: Patent Administration

20060287235 - Crystallization of igf-1: Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method... Agent: Heller Ehrman LLP

20060287228 - Expression of active human factor ix in mammary tissue of transgenic animals: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals that incorporate chimeric DNA molecules according to the present invention. Transgenic animals of the present invention are produced by introducing into developing embryos DNA that encodes Factor IX, such that... Agent: Jayme Huleatt Cooley Godward LLP

20060287227 - Gonadal function improving agents: Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility,... Agent: Edwards & Angell, LLP

20060287233 - Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells: The present invention provides materials and methods for the treatment of diabetes. Using the materials and methods of the invention, the loss of pancreatic β-cells can be slowed and/or prevented. In addition, the materials and methods of the invention can be used to regenerate pancreatic β-cells.... Agent: Connolly Bove Lodge & Hutz LLP Suite 800

20060287236 - Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases: Methods and compositions are provided for the diagnosis and treatment of iron overload diseases and iron deficiency diseases.... Agent: Jones Day

20060287229 - Novel cd40 variants: The invention concerns CD40 skipping 5 nucleic acid sequences and amino acid sequences obtained by alternative splicing of CD40, pharmaceutical compositions comprising said sequences and methods for treatment of a disease, wherein a beneficial therapeutic effect is achieved by the up regulation of the CD40-R-CD40-L interaction. An antibody capable of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060287237 - Rhob as a suppressor of cancer cell growth, cell transformation, and metastasis: The present invention concerns the use of the protein RhoB and its variants to inhibit cancer cell growth, migration, invasion, metastasis, malignant cell transformation, and/or to modulate oncogenic signaling, wherein introducing RhoB directly, or indirectly via a nucleic acid sequence encoding RhoB, into a malignantly transformed cell or a cancerous... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20060287231 - Therapeutic uses of kallikreins: The present invention relates to therapeutic applications of kallikreins and compositions containing them for treating, preventing and/or ameliorating cancers, especially epithelial cancers, such as ovarian, breast and cervical cancer.... Agent: Foley And Lardner LLP Suite 500

20060287234 - Wound healing: Methods for accelerating and/or improving wound healing in a subject by administering vascular endothelial growth factor (VEGF) are provided.... Agent: Genentech, Inc.

20060287238 - Novel combinations of dnak inhibitors with known antibacterial agents: Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such compositions, methods and kits are useful in the treatment of various bacterial infections.... Agent: Norton & Diehl LLC

20060287239 - Biologically active peptides: Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced thereform are also disclosed.... Agent: EagleIPLimited

20060287240 - Method of stimulating prosaposin receptor activity: A method for stimulating prosaposin receptor activity in a cell by transfecting the cell with a DNA or RNA molecule encoding prosaposin or a prosaposin receptor agonist. The DNA or RNA molecule is administered either in vivo or used to transfect neural cells or neural stem cells ex vivo followed... Agent: Kenyon & Kenyon LLP

20060287245 - Anti-tumor agents: A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in... Agent: Wolf Greenfield & Sacks, PC

20060287241 - Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described.... Agent: Astrazeneca R&d Boston

20060287242 - Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions: The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only... Agent: Louis J. Wille Bristol-myers Squibb Company

20060287244 - L-threonine derivatives of high therapeutic index: The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the... Agent: Mark J. Choen, Scully, Scott, Murphy & Presser, P.C.

20060287243 - Stable pharmaceutical compositions including motilin-like peptides: Stable, pharmaceutical compositions including a synthetic motilin-like peptide in a buffered aqueous solution or in an unbuffered aqueous solution are disclosed. The composition provides for a peptide that remains stable and substantially retains its initial potency during extended storage and after steam sterilization.... Agent: Baxter Healthcare Corporation

20060287246 - Remedy for eye diseases accompanied by optic nerve injuries: An object of the present invention is to search for a novel medicinal use of a compound having a secretase inhibitory activity. Because the compound having a secretase inhibitory activity has a remarkable inhibitory effect on retinal neuronal cell death, it is useful as a therapeutic agent for a retinal... Agent: Frishauf, Holtz, Goodman & Chick, PC

20060287247 - Halogen-substituted thienyl compounds: Halogen substituted thienyl compounds exhibit potential as nucleic acid (especially double stranded DNA) binders and as antibiotic compounds. A representative thienyl compound has the structure... Agent: Townsend And Townsend And Crew, LLP

20060287248 - Asymmetric dosing methods: A method of treating, preventing or ameliorating one or more symptoms of hepatitis C, or inhibiting cathepsin activity, in a subject is provided, in which at least one compound (e.g., a HCV protease inhibitor) is administered in one or more discrete dosages over a twenty-four hour time interval in an... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060287249 - Crystalline forms: There is provided EtO2C—CH2—(R)Cgl-Aze-Pab-OH, or a pharmaceutically-acceptable salt thereof, in a form which is substantially crystalline. It has been found that crystalline forms of EtO2C—CH2—(R)Cgl-Aze-Pab-OH have a high chemical and solid slate stability when compared to amorphous forms of the compound.... Agent: Nixon & Vanderhye, PC

20060287250 - Methods for synthesis of acyloxyalkyl derivatives of gaba analogs: The synthesis of 1-(acyloxy)-alkyl carbamates of GABA analogs from 1-haloalkyl carbamates of GABA analogs are described. Also described are new 1-haloalkyl carbamates of GABA analogs.... Agent: Richard F. Trecartin Dorsey & Whitney LLP

20060287251 - Combination therapy for glycaemic control: The present invention relates to method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes mellitus (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus the predi,betic state and/or obesity and to compositions for use in s ch method.... Agent: Osi Pharmaceuticals, Inc.

20060287252 - Substances k01-0509 and process for producing the same: A microorganism belonging to the genus Streptomyces and being capable of producing substance K01-0509-A1 and/or substance K01-0509-A2 is cultured in a medium. Then, the substance K01-0509-A1 and/or the substance K01-0509-A2 having been thus accumulated in the liquid culture medium are collected from the medium. It is expected that the obtained... Agent: Young & Thompson

20060287253 - Compounds and methods for treating seizure disorders: This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287254 - Use of substituted azetidinone compounds for the treatment of sitosterolemia: The present invention is directed to pharmaceutical compositions comprising a sterol absorption inhibitor, a CEPT inhibitor and/or an HMG-CoA reductase inhibitor as well as methods for treating sitosterolemia, hypercholesterolemia, hyperlipidemia, atherosclerosis, mixed dyslopidemia, vascular events prevention and related disorders in a mammal in need thereof by administering said pharmaceutical compositions... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060287255 - C-linked glucuronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth: e

20060287256 - Novel nutraceutical compositions and use thereof: Compositions comprising, as the active ingredients, resveratrol, a derivative, metabolite or analogue thereof, and at least one additional component selected from EGCG, genistein, vitamin E, polyunsaturated fatty acids, gamma-linolenic acid and vitamin K are disclosed. The compositions exert an antiinflammatory effect and may be a food or beverage or a... Agent: Stephen M Haracz Bryan Cave

20060287257 - Pharmaceutical compositions to treat diseases caused by mycobacterium: The invention teaches the synthesis of pharmaceutical composition and methods of synthesis to treat people and animals infected with a pathogenic mycobacterium. In particular the compositions of this invention are suitable for the treatment of tuberculosis, malaria, and other infections diseases caused by mycobacterium.... Agent: Richard F. Stockel

20060287265 - Apoptosis-specific eif-5a and polynucleotides encoding same: The present invention relates to apoptosis specific eucaryotic initiation factor 5A (eIF-5A), referred to as apoptosis-specific eIF-5A or eIF5-A1, nucleic acids and polypeptides and methods for increasing or decreasing expression of apoptosis-specific eIF-5A. The invention also relates to methods of increasing or decreasing apoptosis.... Agent: Kenyon & Kenyon LLP

20060287259 - Compositions and methods for combined therapy of disease: A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to... Agent: Pepper Hamilton LLP

20060287271 - Dinucleoside poly(borano)phosphate derivatives and uses thereof: Dinucleoside poly(borano)phosphates are provided that can be useful for prevention or treatment of diseases or disorders modulated by P2Y receptors such as type 2 diabetes, cystic fibtosis and cancer.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20060287263 - Methods and compositions for inducing antigen-specific immune responses: Vaccine compositions comprising (a) an oligonucleotide, (b) and immune stimulating complex and (c) an antigen induce a strong interferon-gamma immune response. Both oligonucleotides containing immune stimulatory motifs and oligonucleotides lacking immune stimulatory motifs contribute to an interferon-gamma response when administered with an immune stimulating complex.... Agent: Foley And Lardner LLP Suite 500

20060287273 - Methods and reagents for inhibiting cell proliferation: Methods and reagents for reducing expression of proteins involved in intracellular signalling are disclosed. Specifically, siRNA sequences are provided for reducing expression of Src, stat3, and c-myc gene products. Combination treatments are disclosed for inhibiting cell proliferative pathways, and for reducing tumor growth in breast and colon cancer.... Agent: Birch Stewart Kolasch & Birch

20060287272 - Methods for determining specificity of rna silencing and for genetic analysis of the silenced gene or protein: Methods and kits for determining the specificity of siRNAs for their targets are provided. Also provided is a method for performing genetic analysis of the target protein or gene using different versions of a synthetic gene to complement the phenotype induced by RNAi-mediated silencing of the target protein and/or gene... Agent: Dann, Dorfman, Herrell & Skillman

20060287270 - Methods of using redox-active surfactants to control polymer interactions: The present invention provides methods utilizing redox-active surfactants to provide electrochemical control over polymer interactions. In one embodiment, the invention is directed to a transfection method using a redox-active transfection agent that preferentially promotes transfection dependent on the oxidation state of the transfection agent. Accordingly, certain methods according to the... Agent: Godfrey & Kahn, S.c.

20060287262 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked... Agent: Joseph C. Zucchero Keown & Associates

20060287261 - Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides: The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of... Agent: Joseph C. Zucchero Keown & Associates

20060287260 - Oligonucleotides comprising a non-phosphate backbone linkage: One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3′-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20060287274 - Phosphoepoxides, method for making same and uses: e

20060287266 - Rna interference mediated ihibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287267 - Rna interference mediated inhibition of respiratory syncytial virus (rsv) expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating sespiratory syncytial virus (RSV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RSV gene expression... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287264 - Rnai modulation of the bcr-abl fusion gene and uses thereof: The invention relates to compositions and methods for modulating the expression of Bcr-Abl, and more particularly to the down-regulation of Bcr-Abl mRNA and Bcr-Abl protein levels by oligonucleotides via RNA interference, e.g., chemically modified oligonucleotides.... Agent: Fish & Richardson PC

20060287269 - Short interfering nucleic acid hybrids and methods thereof: Disclosed herein are siHybrids used for gene silencing. An siHybrid is a short double-stranded molecule comprised of one strand of DNA and one strand of RNA, annealed together, with a 2-base overhang at each 3′ end. In addition to DNA and RNA, it may contain PNA or other nucleic acid... Agent: Assistant Laboratory Counsel Lawrence Livermore National Laboratory

20060287268 - Splice-region antisense composition and method: Antisense compositions targeted against an mRNA sequence coding for a selected protein, at a region having its 5′ end from 1 to about 25 base pairs downstream of a normal splice acceptor junction in the preprocessed mRNA, are disclosed. The antisense compound is RNase-inactive, and is a phosphorodiamidate-linked morpholino oligonucleotide... Agent: Perkins Coie LLP

20060287258 - Treatment of menorrhagia, dysmenorrhoea or endometriosis: A method of combating menorrhagia, dysmenorrhoea or endometriosis in a female individual, the method comprising administering to the individual at least one agent that that reduces the effect of prokineticin 1 on a prokineticin receptor.... Agent: Nixon Peabody LLP - Patent Group

20060287275 - Partial and full agonists of a1 adenosine receptors: Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, myocardial infarction and hyperlipidemia.... Agent: Brian Lewis Cv Therapeutics, Inc.

20060287276 - Compositions comprising oligosaccharides: The present invention concerns compositions comprising a saccharide for the inhibition of pathogen adhesion to mammalian cells.... Agent: Novartis Corporate Intellectual Property

20060287277 - Novel therapeutic uses of glucan: A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components;... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060287278 - Method for improving water solubility of chitosan: The present invention is directed to a composition comprising: (a) at least one nonderivatized chitosan and (b) at least one solubilizing buffer, as well as methods of preserving contact lens solutions and disinfecting contact lens using such composition.... Agent: Bausch & Lomb Incorporated

20060287279 - Method of assaying an fe-sugar complex: A method for assaying a pharmaceutical product containing a Fe-Sugar complex is described herein. The assay comprises in one embodiment measurement of the molecular weight of the Fe-Sugar complex. The method described herein is robust, reproducible and can serve as a quality assurance method for pharmaceutical purposes.... Agent: Thorpe North & Western

20060287280 - Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex: m

20060287281 - Phosphohalohydrins, process for the production thereof and use thereof: R1 is selected from among —CH3 and —CH2—CH3, Cat+ is an organic or inorganic cation, and n is an integer between 2 and 20, processes for the production thereof and uses thereof, in particular therapeutic uses and for activating primate Tγ9δ2 lymphocytes.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20060287282 - Compositions comprising a sarm ad gnrh agonist or a gnrh antagonist, and methods of use thereof: The present invention relates to compositions comprising a selective androgen receptor modulators (SARM) and a gonadotropin releasing hormone (GnRH) agonist or a GnRH antagonist, and their use, inter-alia for treating hormone-associated conditions in males and females, which arise as a result of androgen decline, suppression or abrogation, or in treating,... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20060287283 - Prodrugs of 9-aminomethyl tetracycline compounds: The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.... Agent: Lahive & Cockfield

20060287284 - Pharmaceutical composition combining tenatoprazole and an anti-inflamatory agent: The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents preferably selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.... Agent: Buchanan, Ingersoll & Rooney PC

20060287285 - Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions: A method and composition for the treatment of hormone allergy is disclosed. The method relates to using progesterone dilutions, or any other steroid hormone, to treat the systemic symptoms of hormone allergy, including pain. The composition of the hormone dilutions ranges from 10−1 to 10−5. The hormone dilution may be... Agent: Baker Botts L.L.P. Patent Department

20060287286 - Phenethanolamine derivatives for treatment of respiratory diseases: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20060287287 - Aminoacetamide acyl guanidines as beta-secretase inhibitors: or a stereoisomer; or a pharmaceutically acceptable salt thereof, wherein R2, R3, R4, R5, R25, R26 and R27 as defined herein, their pharmaceutical compositions and methods of use. These compounds inhibit the processing of amyloid precursor protein (APP) by β-secretase and, more specifically, inhibit the production of Aβ-peptide. The present... Agent: Louis J. Wille Bristol-myers Squibb Company

20060287288 - Antimicrobial composition useful for preserving wood: Antimicrobial compositions useful for preserving wood, and comprising a variety of antimicrobial compounds.... Agent: Rohm And Haas Company Patent Department

20060287289 - Crystalline anhydrous cefdinir and crystalline cefdinir hydrates: A novel crystalline cefdinir anhydrate and novel crystalline cefdinir hydrates, ways to make them and use them, compositions comprising them and made with them, and methods of treatment using them are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20060287290 - Azabicyclic compounds are central nervous system active agents: n

20060287291 - Compounds:

20060287292 - Naphthyridine compounds: Certain naphthyridine compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20060287293 - Heterocyclylalkylamines as muscarinic receptor antagonists: wherein X, Y, and Z are O, S or NR5, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20060287294 - Aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060287295 - Quinazoline derivatives as antiproliferative agents: The invention concerns quinazoline derivatives of Formula (I), wherein each of R1a, R1b, R2, R3 and a have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in... Agent: Morgan Lewis & Bockius LLP

20060287296 - Preparation of hymenialdsine derivatives and use thereof: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α). The chemically-synthesized indoloazepines of the invention also inhibit... Agent: Mcleod & Moyne, P.C.

20060287297 - Tricyclic opioid modulators: The invention is directed to compounds of Formula (I) useful as delta and mu opioid receptor modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.... Agent: Philip S. Johnson Johnson & Johnson

20060287298 - Pharmaceutical for treatment of neurological and neuropsychiatric disorders: e

20060287299 - Combination therapy for dementia, depression and apathy: The invention provides, in part, methods and compositions for treating psychiatric disorders, for example, apathy, dementia, or depression, using combination therapies such a monoamine oxidase inhibitor or a selective serotonin reuptake inhibitor in combination with an anti-psychotic agent.... Agent: Bozicevic, Field & Francis LLP

20060287300 - Anti-infective agents: e

20060287301 - Novel formulations for phenothiazines, including fluphenazine and its derivatives: The invention includes novel formulations of fluphenzine HCl, derivatives thereof and other phenothiazines for the purpose of treating a mammal, preferably a human, in need thereof.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20060287304 - Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient: (wherein all symbols are as defined in the specification) and salt thereof, and peroxisome proliferator activated receptor regulator comprising thereof as active ingredient. Because a compound of formula (I) have an activity of regulating peroxisome proliferator activated receptor regulator, the compound of formula (I) is useful as a hypoglycemic agent,... Agent: Sughrue Mion, PLLC

20060287302 - Mitotic kinesin inhibitors: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20060287303 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Jonatnan P. O'brien Miller, Canfield, Paddock And Stone

20060287305 - Antiparasitic artemisinin derivatives (endoperoxides): This invention relates to the use of certain C-10 substituted derivatives of artemisinin of general formula (I) in the treatment and/or prophylaxis of diseases caused by infection with a parasite, certain novel C-10 substitued derivatives of artemisinin, processes for their preparation and pharmaceutical compositions containing such C-10 substituted derivatives. The... Agent: Jeffrey M. Greenman

20060287306 - Compounds to treat alzheimer's disease: i

20060287307 - Antibacterial compounds:

20060287308 - 3-aminoquinazolin-2,4-dione antibacterial agents: Antibacterial 3-aminoquinazolin-2,4-diones have formula (1) wherein: R1 and R3 include alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclic, and heteroaryl; R5, R6, and R8 include H, alkyl, alkoxy, halo, NO2, CN, NH2, alkyl and dialkylamino; R7 includes hydrogen, alkyl, cycloalkyl, heterocyclic, fused heterocyclic, aryl and fused aryl; J and K are C... Agent: Warner-lambert Company

20060287309 - [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia: wherein G, D, A, Z, Q, X, Y, R1, and R4 through R7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other... Agent: Warner-lambert Company

20060287310 - [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia: wherein G, D, A, Z, Q, X, Y, R1, and R4 through R7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other... Agent: Warner-lambert Company

20060287313 - Isoquinoline compounds and methods of use thereof: The present invention relates to Isoquinoline Compounds, compositions comprising an effective amount of an Isoquinoline Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, Parkinson's disease, renal failure, a vascular disease, or cancer,... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20060287312 - Tetracyclic amino and carboxamido compounds and methods of use thereof: The present invention relates to Tetracyclic Amino Compounds and Tetracyclic Carboxamido Compounds, compositions comprising an effective amount of a Tetracyclic Amino Compound or a Tetracyclic Carboxamido Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic complication, reoxygenation injury resulting from organ transplantation, an... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20060287311 - Tetracyclic sulfonamide compounds and methods of use thereof: The present invention relates to Tetracyclic Sulfonamide Compounds, compositions comprising an effective amount of a Tetracyclic Sulfonamide Compound and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, Parkinson's disease, renal failure, a vascular disease,... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20060287314 - Immunosuppressive effects of pteridine derivatives: This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydro-derivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the... Agent: Clark & Elbing LLP

20060287315 - Pyrazinedicarboxamides and their use: The present invention relates to novel pyridinedicarboxamides, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.... Agent: Jeffrey M. Greenman

20060287316 - Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors: e

20060287317 - Sphingosine kinase inhibitors: The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287319 - Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds: A group of compounds that inhibit HIV replication by blocking HIV entry was identified. One representative compound, designated NB-206, and its analogs inhibited HIV replication (p24 production) with IC50 values at nanomolar levels. It was proved that NB-206 and its analogs are HIV entry inhibitors by targeting the HIV gp41... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20060287318 - Method for treating glaucoma iii b: Provided, among other things, is a method of decreasing intraocular pressure or improving ocular accommodation in an animal, including a human, comprising administering an intraocular pressure decreasing or ocular accommodation improving amount of a compound of the formula (1): Y-Ar⊕•X−... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060287320 - Preparation of thioarabinofuranosyl compounds and use thereof: o

20060287321 - Novel lactam derivatives:

20060287322 - Bicyclic heterocycles as cannabinoind-1 receptor modulators:

20060287323 - Azabicyclic heterocycles as cannabinoid receptor modulators:

20060287324 - Bicyclic heterocycles as cannabinoid-1 receptor modulators:

20060287326 - 17-acetamido-4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.... Agent: Merck And Co., Inc

20060287325 - Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)-: The present invention relates to therapeutic combinations comprising paroxetine or physiologically acceptable salts or solvates thereof and 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS)-6-oxo-hexahydro-pyrrolo[1,2-a]-pyrazin-2-yl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide or pharmaceutically acceptable salts or solvates thereof, to pharmaceutical compositions containing said combinations and their use in the treatment of depression and/or anxiety.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20060287327 - Helix 12 directed non-steroidal antiandrogens: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. The compounds can be formulated together with pharmaceutically acceptable diluents or carriers or otherwise made into any pharmaceutical dosage form.... Agent: Ostrolenk Faber Gerb & Soffen

20060287329 - Amide type carboxamide derivative: and the like; Y1 and Y2 are the same or different and each is a group selected from a halogen atom, a lower alkyl group, a lower alkoxy group, and the like; Ring A is phenyl group, and the like, or a pharmaceutically acceptable salt thereof, which is useful as... Agent: Birch Stewart Kolasch & Birch

20060287328 - Silicon compounds with microbiocidal activity: Fungicidal compounds of formula (1): where X is O or S; RING is phenyl or thienyl; Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by one to four groups R4; R1 is hydrogen,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20060287330 - Substituted melanocortin receptor-specific single acyl piperazine compounds: and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q is a substituted or unsubstituted aromatic carbocyclic ring group, L, R2a, R2b, R3a, R3b,... Agent: Palatin Technologies, Inc.

20060287332 - Melanocortin receptor-specific piperazine and keto-piperazine compounds: and pharmaceutically acceptable salts thereof, where X, W, J, Q, L1, L2, L3, R1a, R1b, R2a, and R2b are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration. Compounds disclosed herein bind to one or more melanocortin receptors and may be... Agent: Palatin Technologies, Inc.

20060287331 - Melanocortin receptor-specific piperazine compounds with diamine groups: and pharmaceutically acceptable salts thereof, where W is a diamine heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, J, Q, L1, L2, L3, R1a, R1b, R2a, R2b and X are as defined in the specification, and the carbon atom marked with an asterisk... Agent: Palatin Technologies, Inc.

20060287334 - Quinoline compounds and pharmeceutical compositions containing them: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060287335 - Serotonergic agents for treating sexual dysfunction: Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT1A receptor antagonists.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP /

20060287333 - Serotonergic agents for treating sexual dysfunction: Methods and compositions are provided for treating sexual dysfunction, e.g., sexual dysfunction associated with drug treatment, using 5-HT1A receptor antagonists.... Agent: Wilmer Cutler Pickering Hale And Dorr LLP /

20060287336 - S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders: This invention relates to pharmaceutical compositions containing S-methyl-dihydro-ziprasidone and to the use of such compound and its pharmaceutically acceptable salts for the treatment of psychiatric and ocular disorders. More specifically, it relates to the use of such compound and its pharmaceutically acceptable salts for the treatment of a disorder or... Agent: Paul H. Ginsburg Pfizer Inc.

20060287337 - Trans-golgi network-associated processes, methods and compositions related thereto: The application discloses methods and compositions related to the modulation of trans-Golgi network-associated processes, including methods and compositions for the modulation of trans-Golgi network-associated proteins and methods for the treatment of disorders associated with trans-Golgi network processes.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20060287338 - Metalloproteinase inhibitor compounds: e

20060287339 - Aza- and polyazanthranyl amides and their use as medicaments: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.... Agent: Novartis Corporate Intellectual Property

20060287340 - 2-aminoquinoline derivatives: [in which R1 and R2 either stand for lower alkyl, lower cycloalkyl, etc., or R1 and R2 together form an aliphatic nitrogen-containing heterocycle with the nitrogen atom to which they bind; R3, R4, R5, R6 and R7 stand for hydrogen, lower alkyl, etc.; R8 stands for lower alkyl, lower alkyloxy,... Agent: Merck And Co., Inc

20060287341 - Triazolopyrimidine cannabinoid receptor 1 antagonists: n

20060287342 - Triazolopyrimidine heterocycles as cannabinoid receptor modulators:

20060287343 - Inhibitors of vegf receptor and hgf receptor signaling: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions... Agent: Joseph C. Zucchero

20060287344 - Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith: wherein R1, R2 and and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related... Agent: Jones Day

20060287346 - Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer: The present invention provides enteric polymer coated tablet formulations for oral administration which comprise a phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes for preparing such formulations and their use in therapy, in particular the treatment of atherosclerosis.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060287345 - Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives as selective non-peptide delta opiod agonists with antidepressant and anxiolytic activity: The present invention relates to the use of 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives according to Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof as selective non-peptide δ-opioid agonists for use in the prevention and/or treatment of... Agent: Philip S. Johnson Johnson & Johnson

20060287347 - Methods for treating smooth muscle disorders using trospium: Methods are disclosed using Trospium Chloride, an antimuscarinic smooth muscle relaxant, for the treatment of urinary incontinence, and other disorders, while avoiding the concomitant liability of adverse side effects associated with conventional antimuscarinic treatment.... Agent: Nields & Lemack

20060287348 - 17-acetamido-4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.... Agent: Merck And Co., Inc

20060287349 - 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20060287350 - Process for making cabergoline: A process for making cabergoline uses silyl-protecting agents to protect the indole nitrogen atom.... Agent: Mark R. Buscher SynthonIPInc

20060287351 - Antibiotic cycloalkyltetrahydroquinoline derivatives: A method of treating a subject for a bacterial infection includes administering to a subject in need of treatment for a bacterial infection an effective amount of a compound represented by structural formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof. The variables in structural formula (I) are... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20060287353 - Method for preventing or treating ischemia-or hemorrhage-induced brain damage using a macrolide compound: Macrolide compound, such as a tacrolimus analogue is provided for use as a neuroprotective agent, particularly, for preventing or treating acute or chronic cerebral neurodegenerative diseases.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060287352 - Modified release compositions comprising tacrolimus: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects... Agent: Cheryl H Agris Phd

20060287354 - Azaindole compounds as kinase inhibitors: The present invention relates to novel azaindole compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20060287355 - Imidazo and thiazolopyridines as jak3 kinase inhibitors: The present invention relates to novel imidazo and thiazolopyridine compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them. Formula (I)... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20060287356 - Thienopyridones as ampk activators for the treatment of diabetes and obesity: The present invention relates to compounds that activate AMP-activated protein kinase (AMPK), including the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders such as diabetes, metabolic syndrome, and obesity.... Agent: Robert Deberardine Abbott Laboratories

20060287358 - Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes: Described is a method for treating an individual having a neurological disorder with an associated mutation or mutations in a gene encoding a lysosomal enzyme. Specifically, the individual is administered a specific pharmacological chaperone for the lysosomal enzyme which increases trafficking of the protein from the ER to the lysosome... Agent: Baker & Botts

20060287357 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors: s

20060287359 - Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases: Compounds for the treatment of estrogen-receptor related maladies are provided. Compounds with anti-androgenic properties also are provided. In particular, the invention provides compounds that are tetrahydroquinoline phenylamide derivatives and are useful for the treatment of breast and prostate cancer, and osteoporosis.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20060287360 - Novel compounds: Novel NH-substituted fused triazoles are inhibitors of the bacterial enzyme S aureus methionyl t RNA synthetase and are of use in treating bacterial infections.... Agent: Swanson & Bratschun L.L.C.

20060287361 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof as opoid receptors ligands: Compounds of general formula: (I) wherein R1, R2, R3 and A are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the treatment of pain and anxiety.... Agent: Cozen O'connor, P.C.

20060287362 - Organic compounds: in salt or zwitterionic form wherein, wherein R1, R2, R3, R4, R5, J, L and M have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds... Agent: Novartis Corporate Intellectual Property

20060287363 - Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht 1f agonists: The present invention relates to compounds of formula I: (I) or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c═ or N═; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 n-alkyl, C3-C6 cycloalkyl-C1-C3... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060287364 - Methods of prevention of infection with hiv/aids, venereal disease and influenza: The invention includes methods for prophylaxis of at least one of infection with HIV/AIDS and venereal diseases, grippe/influenza. The method includes use of materials, in solution, cream, gel and/or tablet form, which possess virucidal and bactericidal characteristics. The method includes applying such materials to a mammal's skin and/or mucous membranes... Agent: Flaster/greenberg P.C. 8 Penn Center

20060287365 - Substituted arylpyrazoles: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20060287366 - Treating pain using selective antagonists of persistent sodium current: The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.... Agent: Allergan, Inc.

20060287367 - Pyridoxamine for the treatment of diabetic kidney disease: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287368 - Amide derivative of amlodipine: A derivative of amlodipine having the following formula is useful as a pharmaceutical, either alone or in combination with amlodipine, in treating angina and hypertension.... Agent: Mark R. Buscher SynthonIPInc

20060287369 - Diarylmethyl and related compounds: wherein R1, R2, R3, R4, R5, R6, R7, Ar1, Ar2, E, a, b, c and z are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore,... Agent: Theravance, Inc.

20060287371 - Epothilone derivatives: e

20060287370 - Isoindolinone kinase inhibitors:

20060287373 - Cathepsin cysteine protease inhibitors: This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibit cathepsins K, L, S and B. These compounds are... Agent: Merck And Co., Inc

20060287372 - Pharmaceutical preparations containing thiazolidinediones showing new therapeutic indications: The present invention refers to new therapeutic applications of pharmaceutical formulations containing, as active principles, thiazolidinediones.... Agent: Jay S Cinamon Abelman Frayne & Schwab

20060287374 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1... Agent: Foley And Lardner LLP Suite 500

20060287375 - Benzisothiazoline derivative, plant disease control agent for agricultural or horticultural use, and pest control agent for agricultural or horticultural use: e

20060287376 - Palladium catalyzed indolization of 2-bromo or chloroanilines:

20060287377 - New benzimidazole derivatives:

20060287378 - Novel pyrroles and imidazoles: Novel imidazoles and novel pyrroles are provided. Also provided are pharmaceutical compositions, methods of making and methods of using the compounds.... Agent: Warner-lambert Company

20060287379 - Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer: The invention relates to a group of novel pyrazole compounds of Formula (I): wherein: R1, R2, R3, M and R5 are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds... Agent: Astrazeneca R&d Boston

20060287380 - Azabicyclo derivatives as muscarinic receptor antagonists: This invention generally relates to muscarinic receptor antagonists of formula (I) which are useful, among other uses for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the... Agent: Ranbaxy Inc.

20060287381 - Enhanced indolinone based protein kinase inhibitors: Hydroxy carboxy pyrrolyl-indolinone derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer. More particularly, alpha-hydroxy-omega-(2-oxo-indolylidenemethyl-pyrrole-3′-carbonyl) amino alkanoic acid and amide derivatives have enhanced and unexpected drug properties as inhibitors of protein kinases... Agent: The Scripps Research Institute

20060287382 - 2-(1h-indolylsulfanyl)-aryl amine derivatives: d

20060287383 - Substance exhibiting antidepressant property: The invention relates to medicine, more specifically to antidepressant pharmacology which selectively improves a diminished mood dominated by asthenic emotions. The inventive antidepressant substance is embodied in the form of N-carbamoyl-methyl-4-phenyl-2-pyrrolidone. Said invention increases the evidence of antidepressant effect after a single dose, prevents sedative and cholinergic effects, avoids the... Agent: Patenttm.us

20060287384 - Lipoic acid concentrate: A water-free concentrate, consisting of ubichinon Q10, a medium-chained triglyceride or triglyceride mixture, α-lipoic acid and/or its derivative as well as one or more emulgators with HLB value between 9 and 19 permitted according to the foodstuff or drug laws has been described.... Agent: Jacobson Holman PLLC

20060287386 - Benzo[b]furane and benzo[b]thiophene derivatives: The present invention relates to benzo[b]furane and benzo[b]thiophene derivatives of the general formula IV as the free base or salts thereof and their use.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20060287387 - Fused tricyclic heterocycles useful for treating hyper-proliferative disorders: e

20060287385 - Small organic molecule regulators of cell proliferation: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20060287388 - Materials and methods for treating coagulation disorders: and pharmaceutically acceptable salts thereof, wherein R1, R3, n and Ar are as defined herein. The compounds of the subject invention can be used to treat at-risk populations thereby bringing relief of symptoms, improving the quality of life, preventing acute and long-term complications, reducing mortality and treating accompanying disorders. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060287389 - Phenethanolamine derivatives for treatment of respiratory diseases: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20060287390 - Topically applied circulation enhancing agent and skin and hair cosmetic and bath agent containing the same: A topically applied circulation enhancing agent suited for application over the entire body which has good transdermal absorptivity and causes little irritation is provided. A topically applied circulation enhancing agent is provided which contains a fatty acid ester denoted by general formula (1):... Agent: Cermak & Kenealy LLP Acs LLC

20060287391 - Phosphodiesterase inhibitor: A PDE inhibitor and a therapeutic agent for a PDE-related disease of the present invention contain astaxanthin and/or esters thereof. The PDE inhibitor of the present invention is useful for treating various diseases exhibiting a relationship to PDEs, e.g., chronic obstructive pulmonary diseases, asthma, chronic artery obstruction, cardiovascular diseases, inflammatory... Agent: Le-nhung Mcleland

20060287392 - Gabapentin compositions: The present invention comprises an organic acid salt of gabapentin, wherein the organic acid is tartaric acid, ethanedisulfonic acid, or maleic acid. Methods for modulating the solubility and dose response of gabapentin are discussed. Methods of making organic acid salts of gabapentin are also discussed.... Agent: Philip S. Johnson Johnson & Johnson

20060287393 - Novel compounds, their preparation and use: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular... Agent: Novo Nordisk, Inc. Patent Department

20060287396 - 4-aryl quinols and analogs thereof as therapeutic agents: wherein: Q is ═O or ═N—S(═O)2—RQ; RQ is —H or optionally substituted C1-7alkyl, C3-20heterocyclyl, or C5-20aryl; Ar is optionally substituted C5-20aryl; RO is an oxy substituent; the bond marked α is a single bond or a double bond; the bond marked β is a single bond or a double bond;... Agent: Nixon & Vanderhye, PC

20060287394 - Composition and method for treating macular disorders: A method and composition for treating a macular condition selected from the group consisting of macular degeneration or macular edema. A therapeutically effective amount of a carbonic anhydrase isoform IX inhibitor is administered to the patient to normalize intracellular pH of retinal pigment epithelial cells. The carbonic anhydrase isoform IX... Agent: Merck And Co., Inc

20060287395 - Pharmaceutical composition for the therapy of lower urinary tract symptoms: A therapeutic agent for lower urinary tract symptoms containing tamsulosin or a pharmaceutically acceptable salt thereof as an effective ingredient.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20060287397 - Dl-hydroxy-alkyl-phenylamides having anticonvulsive activity: New anticonvulsant compounds were synthesized and they include the compounds: DL-2-hydroxy-2-(3′,5′-bistrifluoromethylphenyl)butyramide, DL-2-hydroxy-2-(4′-trifluoromethylphenyl)butyramide, DL-2-hydroxy-2-(3′,4′-dichlorophenyl)butyramide, DL-2-hydroxy-2-(3′-bromophenyl)butyramide, DL-2-hydroxy-2-(4′-bromophenyl)butyramide, DL-2-hydroxy-2-(3′-nitrophenyl)butyramide, DL-3-hydroxy-3-(3′,4′-dichlorophenyl)pentanamide, DL-3-hydroxy-3-(4′-bromophenyl)pentanamide, DL-4-hydroxy-4-(3′,4′-dichlorophenyl) hexanamide and DL-4-hydroxy-4-(4′-bromophenyl)hexanamide. They have a significant anticonvulsant activity against pentylenetetrazol-induced seizures as well as unexpected differences in anticonvulsant activity respect those of the non-halogenated compounds. The invention further provides methods... Agent: Thomas L Peterson

20060287398 - 2-alkylcysteinamide or salt thereof, process for producing these, and use of these: w

20060287399 - Treating pain using selective antagonists of persistent sodium current: The present invention provides methods of treating chronic pain in a mammal by administering to the mammal an effective amount of a selective persistent sodium channel antagonist that has at least 20-fold selectivity for persistent sodium current relative to transient sodium current.... Agent: Allergan, Inc.

20060287400 - Method for treatment and chemoprevention of prostate cancer: This invention relates to the treatment and prevention of prostate cancer More particularly, the present invention provides 1) methods of preventing prostate carcinogenesis in a subject; 2) methods of preventing the recurrence of, suppressing, inhibiting or reducing the incidence of prostate carcinogenesis in a subject, 3) methods of treating a... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20060287401 - Methods for treatment of cardiovascular disorders and diseases: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20060287402 - Cathepsin inhibitors: This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for... Agent: Merck And Co., Inc

20060287403 - Method and composition for treatment of inflammatory and inflammation-related disorders: A method of reducing inflamation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the... Agent: John C. Smith, Esq.

20060281666 - Substitute thiophenes and uses therof: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.... Agent: Astrazeneca R&d Boston

20060281667 - Cardiovascular disease therapies: The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided.... Agent: Fibrogen, Inc. Intellectual Property Department

20060281668 - Vascular disease therapies: The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided.... Agent: Fibrogen, Inc. Intellectual Property Department

20060281669 - Method and compositions for the treatment of diabetes and related complications: The present invention relates to administration of relaxin and related polypeptides to treat a variety of conditions, including diabetes, diabetes-related conditions, Alzheimer's disease, and menopause and related conditions.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20060281670 - Compositions and methods for modulating angiogenesis: Methods and compositions for modulating angiogenesis are disclosed. Such modulation is made possible by the use of NK-B, NK-B analogs, NK receptor agonists and NK receptor antagonists to promote or inhibit angiogenesis. The method for modulating the angiogenic activity of cells comprises contacting cells capable of angiogenesis with an effective... Agent: Godfrey & Kahn, S.c.

20060281671 - Organic compounds: Analogues of the amino acid sequence KAPREKY and their use in screening for compounds which interacts with FcεRIα.... Agent: Novartis Corporate Intellectual Property

20060281676 - Agent and method for the treatment and prevention of tse and method for the production of said agent: The invention relates to an agent and/or pharmaceutical active ingredient and to a method for the treatment, prevention and diagnosis of TSE, and to a method for the production of an agent and/or pharmaceutical active ingredient. According to the invention, peptides and/or nucleotide sequences coding for said peptides are provided... Agent: The Firm Of Karl F Ross

20060281677 - Compositions and methods for intracellular delivery of biotinylated cargo: The invention provides compositions for intracellular delivery of biotinylated cargo. The compositions comprise a complex formed between (a) a fusion protein comprising a protein transduction domain linked to streptavidin and (b) a biotinylated cargo for intracellular delivery. In some embodiments, the protein transduction domain comprises the protein transduction domain of... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20060281672 - Dec-205 (ly 75)/dcl-1 intergenic splice variants associated with hodgkin's disease, and uses thereof: The inventors have identified intergenically spliced DEC-205/DCL-1 mRNAs, which encode the intact DEC-205 ectodomain together with an additional carbohydrate recognition domain, a transmembrane domain and a cytoplasmic domain derived from DCL-1. These DEC-205/DCL-1 intergenic splice variants were identified on Reed-Sternberg cells and thus have application in the therapy and investigation... Agent: Knobbe Martens Olson & Bear LLP

20060281679 - Human fgf-23 gene and gene expression products: This invention relates to human fibroblast growth factor (hFGF-23), to cleavage products of hFGF-23, and to variants thereof and to polynucleotides encoding FGF-23. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating skin, brain and... Agent: Davis Wright Tremaine, LLP

20060281680 - Methods and compositions for modulating vascular integrity: The invention provides methods and compositions useful for modulating vascular integrity.... Agent: Genentech, Inc.

20060281681 - Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly,... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20060281678 - Novel inhibitor of angiogenesis, tumor progression, and metastasis targeting ras signalling pathway: The present invention relates to a novel use of thymosin β10 protein for anti-angiogenesis, anti-tumor progression, and anti-metastasis by targeting a Ras signaling pathway. Particularly, thymosin β10 protein reduces the generation of a Ras-GTP/Raf complex by sequestering Ras-GTP or by interfering with the binding of Ras-GTP to Raf through a... Agent: Sheridan Ross Suite 3500

20060281673 - Novel peptide inhibitor of hiv fusion that disrupts the internal trimeric coiled-coil of gp41: This invention relates to a novel peptide inhibitor of a HIV fusion that disrupts the internal trimeric coiled-coil of gp41, to a pharmaceutical composition that comprise this inhibitor, and to methods of treating immunodeficiency disease, especially HIV, that employ such a pharmaceutical composition.... Agent: Berenato, White & Stavish, LLC

20060281674 - S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment: The present invention relates to a method and composition for inducing lymphocyte proliferation and migration, and for reducing the risks of microbial infections in patients immuno-supressed. The present invention particularly relates to the use of S100 protein, such as MRP, to induce the proliferation, differentiation and release of immune cells... Agent: Ogilvy Renault LLP

20060281675 - Somatogenic therapy using a 20kda placental variant of growth hormone: Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties are reduced or eliminated. In particular, it is directed at a method of treatment whereby the... Agent: Fliesler Meyer, LLP

20060281682 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction... Agent: Fish & Richardson PC

20060281683 - Branched cationic copolymers and methods for antimicrobial use: The invention provides a branched copolymer for the treatment of bacterial, fungal, and viral infections. The branched copolymer is characterized as having (i) at least 10 amino acids, (ii) at least 10% of the amino acids are histidine, (iii) at least 10% of the amino acids are non-histidine, (iv) said... Agent: Connolly Bove Lodge & Hutz LLP

20060281685 - Methods of treatment using novel lhrh antagonists having improved solubility properties: The invention relates to peptides which contain N-methylated amino acid units and have improved water solubility. The invention also relates methods for treating a hormone-dependent tumor or a non-malignant indication that is treatable by LH-RH suppression, the method comprising administering to a patient in need of the treatment a therapeutically... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20060281684 - Polymyxin b analogs for lps detoxification: The invention relates to SAEP II peptide dimers that mimic polymyxin B i.a. in its ability to bind non-covalently the lipopolysaccharide (LPS) of Gram-negative bacteria with high affinity, and therefore to detoxify LPS as polymyxin B does. The dimeric structure is maintained by a pair of disulphide bonds involving the... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20060281686 - Aza-peptides: Provided are peptides comprising at least one azaamino acid and having β-sheet breaking ability, useful in the treatment and prevention of diseases such as alzheimer's disease, Dementia Pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and Vascular Dementia with amyloid angiopathy.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20060281687 - Cyclin groove inhibitors: A is (i) a natural or unnatural amino acid residue having a side chain comprising at least one H-bond acceptor moiety and at least one H-bond donor moiety, or a derivative thereof; or (ii) R(CO), wherein R is a C1-C24 hydrocarbyl group comprising at least one H-bond acceptor moiety and... Agent: Lahive & Cockfield

20060281688 - Administration of hcv protease inhibitors in combination with food to improve bioavailability: Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281689 - Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period: Methods are provided for using at least one novel hepatitis C (“HCV”) protease inhibitor in combination with at least one antiviral and/or immunomodulatory agent, which is different from the at least one HCV protease inhibitor, for treating a wide variety of diseases or disorders associated with hepatitis C virus by... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281690 - Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period: The invention relates to unsolvated and host-guest solvated crystalline forms of (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-L-valyl)(methyl)amino]-2,5-dimethylhex-2-enoic acid, E7974, and their therapeutic uses. Pharmaceutical compositions containing crystalline forms of E7974 and a pharmaceutically acceptable carrier represent one embodiment of the invention. The invention also relates to methods for treating cancer, an inflammatory disorder, an autoimmune... Agent: Nixon Peabody, LLP

20060281691 - Method of treating obesity: Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.... Agent: Davidson, Davidson & Kappel, LLC

20060281692 - Use of derivatives of succinate esters for the treatment of dementia: The use of extract form Wangla (coeloglossum viride (L) Hartm. Var. Bracteatum (Willd.) Richter), succinate derivative esters, and a derivative and pharmaceutical acceptable salts thereof, for the manufacture of a pharmaceutical preparation for the treatment of dementia, particularly for the treatment of Alzheimer' disease and Vascular dementia. Through Animal experiment,... Agent: Townsend And Townsend And Crew, LLP

20060281694 - Glucose levels: Disclosed are methods and compositions for improving blood glucose levels in a subject in need thereof.... Agent: Nada Jain, P.C.

20060281693 - Renal function improvement: This invention relates to a method of improving renal function comprising administering to a subject in need thereof a composition comprising the inventive compounds. Also disclosed is a method of improving renal function where the subject is at risk of or suffering from renal failure.... Agent: Nada Jain, P.C.

20060281695 - Control of parasites in animals by n-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and n-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives: Methods for treating an animal for endo and/or ecto parasite infestation and/or for protecting an animal from endo and/or ecto parasite infestation using N-phenyl-1,1,1-trifluoromethanesulfonamide compounds are provided, together with methods of making the same compounds, and methods of using the same compounds to treat parasite infestations in vivo or ex... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281701 - Antisense antiviral compounds and methods for treating a filovirus infection: The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg... Agent: Perkins Coie LLP

20060281702 - Combinatorial selection of phosphorothioate aptamers for rnases: The present invention includes the selection and isolation of thioaptamers that target the ribonuclease domains of enzymes, e.g., HIV reverse transcriptase.... Agent: Chalker Flores, LLP

20060281696 - Decoy-oligonucleotide-inhibition of cd40-expression: The present invention relates to decoy oligonucleotides with the nucleic acid sequence according to SEQ ID NO: 1 to 36 and their use as pharmaceutical agents.... Agent: Fulbright & Jaworski L.L.P.

20060281697 - Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia: The present invention relates to methods and kits for detecting several polynucleotide sequence found to be indicative of a poor prognosis of B-CLL. All the polynucleotides are transcribed from a region on human chromosome 12p21-22. Most of the polynucleotides do not encode larger polypeptides, but may encode small peptides, they... Agent: Hunton & Williams LLP Intellectual Property Department

20060281699 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production: A method for identifying compounds that inhibit amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a PROTEASE polypeptide, or fragment thereof, and measuring a compound-PROTEASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure indicators including cleaved protease substrate and/or amyloid... Agent: Synnestvedt & Lechner, LLP

20060281698 - Modulation of apolipoprotein (a) expression: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.... Agent: Knobbe, Martens, Olson & Bear, LLP

20060281704 - Regulation of endogenous gene expression in cells using zinc finger proteins: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.... Agent: Robins & Pasternak

20060281700 - Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators: e

20060281703 - Treatment of disease using an improved regulated expression system: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and... Agent: Foley And Lardner LLP Suite 500

20060281705 - A1 adenosine receptor agonists: e

20060281706 - Phosphonate compounds: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper Rudnick Gray Cary US LLP

20060281708 - Fluorinated glucosamine analogs useful for modulating post-translational glyscosylations on cells: The present invention provides compositions and methods for inhibiting cell migration, e.g., lymphocytes and inflammation. The invention also provides an improved process for preparing fluorinated N-acetylglucosamines.... Agent: Fish & Richardson PC

20060281707 - Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals: The present invention discloses a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating organ lesions caused by toxicants and drugs. A preparation comprising N-acetyl-D-glucosamine as main active component for treating organ lesions caused by toxicants and drugs exhibits merits of a directive action mechanism, significant therapeutical effects... Agent: Antonelli, Terry, Stout & Kraus, LLP

20060281709 - Anti fibrotic agent containing sphingosine 1-phosphate receptor agonist or sphingosine 1-phosphate as active ingredient: An anti fibrotic agent, comprising a sphingosine 1-phosphate (S1P) receptor agonist or sphingosine 1-phosphate (S1P) as an active ingredient. Since an S1P receptor agonist, particularly S1P, has activity of inhibiting fibrosis in various organs, it is useful in preventing and/or treating diseases caused by fibrosis in organs, such as pulmonary... Agent: Sughrue Mion, PLLC

20060281710 - 17ss-hsd1 and sts inhibitors: The present invention relates to novel substituted steroid derivatives which represent selectiv inhibitors of the 17β-hydroxysteroid dehydrogenase type I (17β-HSD1) and, in addition, which may represent inhibitors of the steroid sulphatase, as well as to their salts, to pharmaceutical preparations containing these compounds and to processes for the preparation of... Agent: Crowell & Moring LLP Intellectual Property Group

20060281711 - Il-12 modulatory compounds: The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.... Agent: Edwards & Angell, LLP

20060281712 - Pyrimidine compounds: This invention relates to a method for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, or tissue injuries. The method includes administering to a subject in need thereof an effective amount of one or more compounds of formula (I). Each variable in this formula is defined in the... Agent: Fish & Richardson PC

20060281713 - 5-thiopiperdinyl prostaglandin e analogs: i

20060281714 - Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss: This invention relates to pharmaceutical preparations comprising certain types of bisphosphonates and certain types of Cathepsin K inhibitors, in particular in the prevention and treatment of bone metastases, tumor-induced hypercalcemia, tumor growth, tumor-induced bone loss and bone loss diseases such as osteoporosis or cancer-therapy-induced bone loss... Agent: Novartis Corporate Intellectual Property

20060281715 - Phosphates of secondary alcohols: According to the invention, there is provided a phosphate derivative of a compound having a secondary hydroxy group. The compound having a secondary hydroxyl group may, for example, be chosen from pravastatin, atorvastatin venlafaxine, their derivatives and mixtures thereof.... Agent: Reed Smith LLP

20060281716 - Alkaloid formulations: There is provided an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents.... Agent: Reed Smith LLP

20060281717 - 11a, 12-derivatives of tetracycline compounds: 11a, 12-dehydrotetracycline compounds are described.... Agent: Lahive & Cockfield

20060281718 - Treatment of vr1-antagonist-induced increase in body temperature with an antipyretic agent: The present invention relates to a method of reducing a VR1-antagonist-induced increase in body temperature in a mammal in need thereof, comprising the step of administering an antipyretic agent to the mammal and the like.... Agent: Us Patent Operations/rvp Dept 4300 M/s 28-2-c

20060281720 - 5-androstenediol as an inhibitor of gliomas: The invention relates to the field of pharmaceuticals for tumor-inhibitory effects. The 5-androstene 3β,17α diol (αAED) and 5-androstene 3β,17β diol (βAED), their esters and ethers, are taught herein to achieve tumor-inhibiting effect. The invention also relates to the field of pharmaceuticals for tumor-inhibitory effects and the use of 5-androstene 3β,7β,17β... Agent: Castellano Malm Ferrario & Buck PLLC

20060281719 - Oestrogen-17-sulphamates as inhibitors of steroid sulphatase: wherein R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of... Agent: Frommer Lawrence & Haug

20060281721 - Hrt formulations: HRT formulations containing low amounts of estradiol and NETA are prepared.... Agent: Novo Nordisk, Inc. Patent Department

20060281722 - Compounds and uses thereof: The invention features charge-modified antidepressants and compounds conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a compound of the invention.... Agent: Clark & Elbing LLP

20060281723 - Folic acid-containing pharmaceutical compositions, and related methods and delivery systems: This invention provides folic acid-containing pharmaceutical compositions comprising either an oral contraceptive or a hormone replacement composition. This invention also provides methods of administering folic acid to a subject using the instant pharmaceutical compositions. Finally, this invention provides a drug delivery system useful for administering the instant pharmaceutical compositions.... Agent: Philip S. Johnson Johnson & Johnson

20060281724 - Methods for treating shock: The invention relates to methods of treating shock in a subject by administering a pharmaceutically effective amount of androstenetriol (AET), androstenediol (AED) or derivatives thereof to a subject suffering from or exhibiting the symptoms of shock. In one particular embodiment, the subject is suffering from hemorrhagic shock. The invention also... Agent: Castellano Malm Ferrario & Buck PLLC

20060281725 - Agents and crystals for improving excretory potency of urinary bladder: Agents for improving potentcy of the urinary bladder which comprise an amine compound of non-carbamate-type having an acetylcholinesterase-inhibiting action. Particularly, crystals of a tricyclic, condensed, heterocyclic derivative are provided, which possess an excellent action to inhibit acetylcholinesterase and an action to improve the excretory potency of the urinary bladder. As... Agent: Wenderoth, Lind & Ponack, L.L.P.

20060281728 - 3-substituted beta-lactamyl vasopressin v1a antagonists: Novel 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof are described. Methods for using 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor are also described.... Agent: Barnes & Thornburg LLP

20060281729 - Macrocyclic heterocyclic aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281727 - Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to fused phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-RV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20060281726 - Piperidine derivatives for the treatment of chemokine or h1 mediated disease state: The present invention provides a compound of a formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.... Agent: Fish & Richardson P.C.

20060281730 - Aspartyl protease inhibitors: Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281731 - Substituted lactams and their use as anti-cancer agents: This invention relates to certain substituted lactam compounds of the formula (I), particularly caprolactam compounds, which are useful for the treatment of cancer.... Agent: Novartis Corporate Intellectual Property

20060281732 - Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-n-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them: i

20060281733 - 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases: Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration... Agent: Foley & Lardner LLP

20060281734 - Amide derivatives: The invention concerns amide derivatives of Formula (Ia) wherein X is —NHCO— or —CONH—; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino and... Agent: Morgan Lewis & Bockius LLP

20060281735 - Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic: The present invention provides novel antipsychotic therapies and compositions useful therein and provides methods for identifying new candidate molecules for the treatment of psychosis based on the proportional binding affinities for α2 adrenergic and D2 dopamine receptors.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060281736 - Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent: A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous, separate or spread over time in the treatment of cancer. According to the invention, the other anti-cancer agent is... Agent: Hedman & Costigan P.C.

20060281737 - Cyclohexyl sulphones as gamma-secreatase inhibitors: s

20060281738 - 2-naphthylimino-1,3-thiazine derivative:

20060281740 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20060281739 - Compositions and methods for treatment of eye disorders: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a... Agent: Wilson Sonsini Goodrich & Rosati

20060281741 - Quinoline derivatives as antibacterial agents: a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, polyhaloC1-6alkyl, C1-6alkyl, Ar or Het; p is an integer equal to 1 or 2; R2 is C1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy or C1-6alkylthio; R3 is Ar, Het or Het1;... Agent: Philip S. Johnson Johnson & Johnson

20060281742 - Amines that inhibit a mammalian anandamide transporter, and methods of use thereof: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20060281744 - Inhibitors of soluble adenylate cyclase: The invention relates to compounds of general Formula I, the production thereof, and the use thereof as a medicinal product.... Agent: Millen, White, Zelano & Branigan, P.C.

20060281743 - Isoquinolinone potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20060281745 - Use of pde4 inhibitors for the treatment of diabetes mellitus: The invention relates to the use of certain known PIDE4 inhibitors for the treatment of diabetes mellitus and accompanying disorders thereof.... Agent: Nath & Associates PLLC

20060281747 - 1,2-di(cyclic) substituted benzene derivatives: wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH... Agent: Choate, Hall & Stewart LLP

20060281746 - Cyclopropyl derivatives as nk3 receptor antagonists: The present invention relates to cyclopropyl derivatives of formula (I) and salt thereof. These compounds are NK3 receptor antagonists and may therefore be useful for treatment of diseases where the NK3 receptor is implicated, e.g. psychotic disorders.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20060281748 - Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux: One aspect of the present invention relates to a method of treating or preventing pathologic effects of hyperglycemia and/or increased fatty acid flux in a subject in need of such treatment or preventive therapy. This method involves administering a composition containing a therapeutically effective amount of a ROS inhibitor to... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20060281749 - Method for treating glaucoma iv b: Provided, among other things, is a method of decreasing intraocular pressure or improving ocular accommodation in an animal, including a human, comprising administering an intraocular pressure decreasing or ocular accommodation improving amount of a compound of the formula (I): Het-Y.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20060281750 - Heteroaryl 11-beta-hydroxysteroid dehydrogenase type i inhibitors: o

20060281751 - Raf inhibitor compounds and methods of use thereof: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells,... Agent: Viksnins Harris & Padys Pllp

20060281752 - Method for the normalization of sexual response and amelioration of long term genital tissue degradation: The present invention provides, in one embodiment, a method of normalizing the timing of sexual response in a mammal comprising the administration of an amount of a central nervous system sexual response initiator in an amount sufficient to produce genital vasodilation but less than the amount required to produce effective... Agent: Wood, Phillips, Katz, Clark & Mortimer

20060281753 - 4-(aminomethyl)-piperidine benzamides as 5ht4 - antagonists: The present invention is concerned with novel compounds of formula (I) having 5HT4-antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds.... Agent: Philip S. Johnson Johnson & Johnson

20060281754 - Method of treating liver disease: Treating diseased or damaged tissue, particularly the liver, using stem cells. The hepatic stem cell population of a subject suffering from diseased or damaged tissue can be expanded by administering at least one regulator of the sympathetic nervous system. The regulator can be an adrenoceptor agonist or antagonist, adrenoceptor antagonists,... Agent: Stites & Harbison, PLLC

20060281755 - Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators: e

20060281756 - Synthesis of 3-amino-4-substituted pyrazole derivatives: This application discloses a novel process to synthesize 3-amino-4-substituted pyrazole derivatives, which may be used, for example, as intermediates to prepare compounds having, for example, pharmaceutical utility.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281757 - Phenyl sulfone derivatives and their use in the treatment of cns disorders: This invention relates to novel phenyl sulfone compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060281759 - Succinate and malonate salt of trans 4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament: 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine hydrogen succinate or hydrogen malonate, pharmaceutical compositions containing these salts and the medical use thereof, including for the treatment of schizophrenia and other psychotic disorders. Also described are methods for the preparation of 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and medical uses thereof.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20060281758 - Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine: A compound 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-2,2-dimethylpiperazine and salts thereof, pharmaceutical compositions comprising the compound and salts, and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20060281761 - 4-azasteroid derivatives as androgen receptor modulators: Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient.... Agent: Merck And Co., Inc

20060281760 - Tubulin inhibitor and process for its preparation: The invention provides 6-chloro-5-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-2-pyrazin-2-yl-N-[(1S)-2,2,2-trifluoro-1-methylethyl]pyrimidin-4-amine hemifumarate which is a tubulin inhibitor useful in the treatment of cancer and processes of making said hemifumarate.... Agent: Wyeth Patent Law Group

20060281762 - 1,3-benzoxazolyl derivatives as kinase inhibitors: The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases. (I)... Agent: Millen, White, Zelano & Branigan, P.C.

20060281764 - Aminopyrimidines as kinase modulators: where R3, B, Z, Q, p, q and R1 are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a... Agent: Philip S. Johnson Johnson & Johnson

20060281763 - Carboxamide inhibitors of tgfbeta: Certain appropriately substituted forms of pyrimidine having a pyridylamine group at C-4 of the pyrimidine and an amide group on the pyridine ring are useful in the treatment of conditions associated with excessive TGFβ activity.... Agent: Morrison & Foerster LLP

20060281765 - Process for producing substituted aniline compound: r

20060281766 - Fungicidal mixtures:

20060281767 - Triazoloypyrimidines:

20060281769 - Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators:

20060281768 - Thienopyrimidine and thienopyridine kinase modulators: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use... Agent: Philip S. Johnson Johnson & Johnson

20060281770 - Method of treating an anxiety disorder: Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other... Agent: Fitzpatrick Cella Harper & Scinto

20060281771 - Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators: x

20060281772 - Alkylquinoline and alkylquinazoline kinase modulators: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in... Agent: Philip S. Johnson Johnson & Johnson

20060281773 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other... Agent: Robert Deberardine Abbott Laboratories

20060281774 - Pyrimidine derivatives for the treatment of abnormal cell growth: wherein R1-R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions... Agent: Pfizer Inc

20060281775 - Two-component pharmaceutical composition for the treatment of pain: The present invention is directed to a pharmaceutical composition that includes a combination of about 2-5 milligrams of a non-steroidal anti-inflammatory drug and from about 2-30 milligrams of an opioid analgesic in a single pharmaceutical dosage unit that can provide effective pain management with the added benefit of reduced side... Agent: Faegre & Benson LLP Patent Docketing

20060281776 - Isotope labeled camptothecin derivatives: The present invention provides isotope stable labeled camaptothecin analogs including irinotecan and SN-38, a process for their preparation and their use as internal standard in analytical methods.... Agent: Pfizer Inc

20060281777 - Process for preparing crystalline form i of cabergoline: A process for producing crystalline form I of cabergoline, which process comprises the preparation of Form V using heptane as precipitation solvent, and its exclusive conversion into crystalline Form I of cabergoline. The present crystallization process from toluene-heptane solvent system for form V involves “reverse addition” of toluene-cabergoline concentrate to... Agent: Pfizer Inc

20060281778 - Compounds for inhibiting ksp kinesin activity: The present invention provides compounds of Formula I (wherein R1, R3, X, W, Z and ring Y are as defined herein). The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases or disorders associated with KSP kinesin activity and for inhibiting KSP kinesin... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20060281779 - 7-(4-substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative: e

20060281780 - Pest control agents: There is provided a pest control agent comprising a compound represented by formula (I) as active ingredient.... Agent: Heller Ehrman White & Mcauliffe LLP

20060281781 - Preventive and therapeutic medicament for gastroesophageal reflux disease: wherein R1 and R2 independently represent a hydrogen atom or a lower alkyl group; A represents a group selected from the group consisting of 1-azabicyclo[3.2.2]nonyl group, 1-azabicyclo[2.2.2]octyl group, or an N-oxide thereof, or a pharmaceutically acceptable salt thereof or a hydrate thereof has both improving effect on enterokinetic functions and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20060281783 - Compositions and methods of treating middle-of-the night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.... Agent: Townsend And Townsend And Crew, LLP

20060281782 - Method for the enantioselective preparation of sulphoxide derivatives: The invention relates to a method for the enantioselective preparation of substituted sulphoxide derivatives. The method comprises carrying out an enantioselective oxidation of a sulphide of general formula (I): A-CH2—S—B (I), where A=a variously-substituted pyridyl nucleus and B=a heterocyclic group with a benzimidazole or imidazopyrdyl nucleus, by means of an... Agent: Buchanan, Ingersoll & Rooney PC

20060281784 - Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament: The invention relates to novel benzimidazole and imidazopyridine derivatives having general formula (I), which have a good affinity with certain sub-types of melanocortin receptors, particularly MC4 receptors. Said derivatives are particularly suitable for the treatment of pathological states and diseases involving one or more melanocortin receptors. The invention also relates... Agent: Hunton & Williams LLP Intellectual Property Department

20060281785 - Compound artemisinin: The present invention provides a novel combination comprising artemisinin in the form of tablets and related dosage forms for pediatric use, such as granules, suppository, suspension syrup and dry powder, for the treatment of human malarias including multiple-resistant subtertian malaria, tertian malaria and quartan malaria. Said combination is comprised of... Agent: Connolly Bove Lodge & Hutz, LLP

20060281786 - Compounds having activity at 5ht2c receptor and uses thereof: Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is —NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Method of preparation and uses thereof in therapy, such as for example in treatment of... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20060281787 - Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases: In a second embodiment, the invention provides a method of treating androgen-independent prostatic adenocarcinoma comprising administering to a patient in need thereof a therapeutically effective amount of compound of formula (I) or a pharmaceutically acceptable salt thereof. In a third embodiment, the invention provides a method of treating an AKT-mediated... Agent: Eli Lilly & Company

20060281788 - Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor:

20060281789 - Protein kinase inhibitors:

20060281790 - Combination: (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.... Agent: Novartis Corporate Intellectual Property

20060281791 - Methods of increasing proliferation of adult mammalian cardiomyocytes through p38 map kinase inhibition: Compositions and methods for increasing proliferation and/or de-differentiation of postmitotic mammalian cardiomyocytes are disclosed to slow, reduce, or prevent the onset of cardiac damage. In addition, the methods and compositions of the invention can used to produce de-differentiated cardiomyocytes, which can then be used in tissue grafting, implantation or transplantation.... Agent: Nutter Mcclennen & Fish LLP

20060281792 - Parasiticide formulations suitable for dermal application: The present invention relates to formulations for the dermal control of parasitic insects on animals, having the following composition agonists or antagonists of the nicotinergic acetylcholine receptors of insects in a concentration of from 1 to 20% by weight based on the overall weight of the formulation; solvents from the... Agent: Jeffrey M. Greenman

20060281793 - Pharmaceutical composition for the management of tumors: The present invention relates to the effect of naturally occurring compounds on tumor development. As an example of proof, we used low; non-toxic doses of three compound e.g. Calcium D-glucarate, a naturally occurring Ca++ salt of D-glucaric acid; Nicotinamide (NA), a naturally occurring vitamin and butyric acid (BA), a naturally... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20060281795 - Benzinidazole derivative and use as aii receptor antagonist: wherein R2, R3, R4, R5, R6, R7 and R8 are each independently a hydrogen atom or a C1-6 alkyl, or a salt thereof. The compound of the present invention is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and metabolic... Agent: Takeda Pharmaceuticals North America, Inc Intellectual Property Department

20060281794 - Erg channel openers for the treatment of cardiac arrhythmias: This invention relates to the use of ERG channel openers for the treatment of cardiac arrhythmias, and to the use of specific compounds for such treatment. In a separate aspect the invention provides novel compounds useful as ERG channel openers.... Agent: Birch Stewart Kolasch & Birch

20060281796 - Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to fused indole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also... Agent: Merck And Co., Inc

20060281797 - Neurorestoration with r(+) pramipexole: Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's... Agent: Patrea L. Pabst Pabst Patent Group LLP

20060281798 - Methods of using thiazolidinedithione derivatives: Methods of using thiazolidinedithione derivatives to treat cancer, neurodegenerative disease, diabetes, renal disease or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20060281799 - Antagonists of the vanilloid receptor subtype 1 (vr1) and use thereof: t

20060281800 - Polymorphic form of olmesartan and process for its preparation: A process for the preparation of a novel crystalline polymorph of olmesartan medoxomil, designated Form G, is provided comprising the steps of (a) preparing a solution comprising olmesartan medoxomil and one or more solvents selected from the group consisting of a nitrile, alcohol and mixtures thereof at a suitable temperature... Agent: M. Carmen & Associates, PLLC

20060281801 - Process for the preparation of valsartan and its intermediates: The present invention relates to an improved process for the preparation of valsartan and its intermediates in substantially pure enantiomeric form. In particular, the present invention provides a process for preparing benzyl valsartan intermediate substantially free of organotin impurities. The valsartan produced from such benzyl valsartan intermediate requires significantly lower... Agent: Blank Rome LLP

20060281802 - Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use: or pharmaceutically acceptable salts thereof. The present invention also includes pharmaceutical compositions comprising an effective amount of a compound of Formula 1 in admixture with a pharmaceutically acceptable carrier or excipient. The compositions may include additional therapeutic agents for combination therapy. The present invention provides a new class of pharmaceutically... Agent: Gibbons, Del Deo, Dolan, Griffinger & Vecchione

20060281803 - Pyrazole modulators of metabotropic glutamate receptors: The present invention is directed to compounds which are allosteric modulators of metabotropic glutamate receptors, including the mGluR5 receptor, and which are useful in the treatment of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to... Agent: Merck And Co., Inc

20060281804 - Novel cycloalkyl'b! condensed indoles: The present invention relates to compounds that are useful in the treatment of human papillomaviruses, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20060281805 - Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists: This invention relates to the derivatives of substituted azabicyclo hexanes. The compounds of this invention can function as muscarinic receptor antagonists and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for... Agent: Ranbaxy Inc.

20060281806 - Treatment and inhibition of disease conditions using flexible heteroarotinoids: The present invention contemplates methods of treating, reducing, inhibiting or preventing several diseases by the administration of flexible heteroarotinoids. Among the diseases or conditions which can benefit from treatment with flexible heteroarotinoids as described herein are, (1) cancers and other diseases that involve abnormal differentiation, (2) diabetes, (3) hemophelia, (4)... Agent: Dunlap, Codding & Rogers P.C.

20060281808 - Process to extract quassinoids: A means for the extraction and crystallization of quassinoids such as quassin and neoquassin from natural sources containing these compounds, using compounds that are Generally Recognized As Safe by the U.S. Food and Drug Administration is provided. In particular, a means for extraction that does not require use of lead... Agent: Miles & Stockbridge PC

20060281807 - Quassinoid compositions for the treatment of cancer and other proliferative diseases: The invention provides quassinoid compounds that are useful in treating cancer. The invention further provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of killing a cancer cell, and a method of treating cancer in a mammal.... Agent: Leydig Voit & Mayer, Ltd

20060281809 - Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating... Agent: Morrison & Foerster LLP

20060281810 - Novel anthranilic acid derivatives: t

20060281811 - Synthesis of taxol enhancers: In Structural Formulas (I)-(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20060281812 - Novel 3,3-diphenylpropylamines useful in therapy:

20060281813 - Methods of treating hyperproliferative cell disorders: Disclosed are methods of treating subjects suffering from hyperproliferative cell disorders which consist of administering to those subjects a combination treatment of a specific retinoid and optionally a growth factor receptor inhibitor.... Agent: Charles C Achkar

20060281814 - Conjugated linolenic acids and methods for commerical preparation and purification: A method for the preparation and purification of conjugated linolenic acids is described. The method comprises blending a mixture of vegetable oils and or fats including various concentrations of alpha or gamma and or both linolenic acids with a base. The method transforms approximately over two thirds of α-linolenic acid... Agent: Knobbe Martens Olson & Bear LLP

20060281815 - Conjugated linolenic acids and methods of preparation and purification and uses thereof: This invention relates to a new conjugated linoleic acids, a process for preparation thereof and method of use. Thus this invention is concerned with the preparation and purification of conjugated linoleic acids from materials rich in alpha or gamma linoleic acids. The reaction produces a mixture containing a 1:1 ratio... Agent: Knobbe Martens Olson & Bear LLP

20060281816 - Pregabalin free of lactam and a process for preparation thereof: The present invention encompasses Pregabalin substantially free of Lactam and a process for obtaining Pregabalin substantially free of Lactam comprising extracting an acidic mixture containing a complex of Pregabalin with a strong mineral acid, with a C3-8 alcohol; and combining the organic phase with an organic base.... Agent: Kenyon & Kenyon LLP

20060281817 - Treatment for neurodegenerative diseases: A method of treating a neurodegenerative disease in a subject in need thereof comprises: (a) administering the subject an ornithine decarboxylase inhibitor such as alpha-difluoromethylornithine or a pharmaceutically acceptable salt or prodrug thereof in an amount effective to treat the disease; and concurrently (b) administering the subject a polyamine or... Agent: Myers Bigel Sibley & Sajovec

20060281818 - Method for treating mucosal disorders: Provided is a method for treating mucosal disorders using a specific prostaglandin compound. The prostaglandin compound induces a conformational change in the tight junction that results in recovery of mucosal barrier function. Accordingly, the prostaglandin compound used herein is useful for the treatment of mucosal disorders.... Agent: Sughrue Mion, PLLC

20060281819 - Suppression of hiv-1 replication via inhibition of human flap endonuclease-1-mediated hiv-1 central dna flap processing: FEN-1 is involved in processing HIV central DNA flap (CDF) and is a target for intervention of HIV-1 replication. Inhibition of HIV-1 CDF removal by expression of D181A FEN-1 mutant suppresses viral DNA replication, further demonstrating that FEN-1 is a target. Methods of identifying and using molecules that inhibit FEN-1... Agent: Perkins Coie LLP

20060281820 - Lfa-1 inhibitors and use thereof: The present invention provides an LFA-1 inhibitor comprising at least one member selected from the group consisting of polyamines represented by general formula (1) and pharmaceutical acceptable salts thereof: NH2—(CH2)m1-(NH)p1-(CH2)m2-(NH)p2-(CH2)m3-(NH)p3-(CH2)m4-(NH)p4-(CH2)m5-NH2 (1), wherein at least two of m1 to m5 exceed 0, each of m1 to m5 is independently an integer... Agent: Steptoe & Johnson LLP

20060281821 - Retinoid replacements and opsin agonists and methods for the use thereof: Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.... Agent: Townsend And Townsend And Crew, LLP

20060281822 - Treatment and prevention of elevated homocysteine: A method for reducing elevated levels of homocysteine in a person comprising the steps of measuring the level of homocysteine in a person; detecting an elevated level of homocysteine in the person; and responsive to said step of detecting, administering to said person a nutritional supplement comprising dimethyl sulfone.... Agent: Mcandrews Held & Malloy, Ltd

20060276372 - Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders: A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a...

20060276373 - Neuroprotective complex for treatment of cerebral ischemia and injury: The invention provides a pharmaceutical composition useful in treating cerebral ischemia and traumatic cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition,...

20060276374 - Use of an agent that restores tissue perfusion and oxygenation: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and...

20060276377 - Factor vii or viia polypeptide variants: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside...

20060276375 - Gpi anchored glycoprotein aca as a novel tumor marker: Described is a GPI-anchored surface glycoprotein having a GPI-anchor which is characterized by a non-acetylated inositol ring and diacyl glycerol as lipid tail of the anchor. A particular glycoprotein of the invention, ACA, is strongly expressed in melanoma cells, some leukemia cells and other tumor cells, thus, is an useful...

20060276376 - Increasing functional glycosylation of alpha-dystroglycan in the treatment of muscle degeneration: Disclosed is a method for the prevention and/or treatment of muscle degeneration. In this method, a subject recognized as having muscle degeneration is treated with a composition effective to increase functional glycosylation of α-dystroglycan in an affected tissue in the subject. Functional glycosylation is to be increased to an extent...

20060276378 - Methods and pharmaceutical compositions for treating sepsis: Methods and compositions for treating and preventing sepsis are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist in combination with an antibiotic agent. The invention further encompasses pharmaceutical compositions comprising a combination of an A1 adenosine receptor...

20060276379 - Binding peptides specific for the extracellular domain of erbb2 and uses therefor: The invention provides methods and compositions for diagnosing and treating subjects using EBPs. Specifically disclosed are peptides and peptidomimetics that bind selectively to the extracellular domain of ErbB2. These compositions are useful in the prevention and treatment of disorders characterized by ErbB2 overexpression (e.g., breast cancer)....

20060276380 - Antimicrobial peptide, compositions, and uses therefor: The invention refers to small peptides with low hemolytic activity, presenting similar antiparasitic, antifungal and antibacterial activities. More specifically, it refers to a peptide called gomesin, with 18 amino acid residues, configured as a hairpin structure consisting of two anti-parallel beta-folded sheets joined by a beta turn, containing four invariable...

20060276396 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention...

20060276385 - Anti-inflammatory agents and methods of their use: The present disclosure provides compositions and methods for reducing or inhibiting vascular inflammation, for example inflammation resulting from unstable blood flow conditions such as oscillatory shear. Representative compositions include an antagonist of BMPs, for example BMP4, or BMP receptors, for example BMPR-I and/or BMPR-II, in an amount sufficient to for...

20060276390 - Combined treatments comprising synthetic peptide copolymers for preventing graft rejection: Compositions and methods for the treatment of graft rejection associated with transplantation of tissues and organs include combined treatment involving at least one agent selected from Copolymer 1, a copolymer 1-related heteropolymer or an ordered peptide in combination with at least one additional known immunosuppressive agent. Compositions and methods for...

20060276398 - Combined use of factor vii polypeptides and factor viii polypeptides: The invention concerns a pharmaceutical preparation comprising a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide. The invention also concerns use of a factor VII or factor VII-related polypeptide and a factor VIII or factor VIII-related polypeptide for manufacture of a medicament for pharmaceutical...

20060276397 - Crystallization of igf-1: Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method...

20060276389 - Fugetactic proteins, compositions and methods of use: This invention relates to compositions and methods that modulate the movement of cells with migratory capacity. More specifically, the invention relates to compositions and methods for promoting migratory movement, fugetaxis, of cells from a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions...

20060276383 - Full length polynucleotide coding chicken type ii collagen and the use of it: The present invention relates to a nucleic acid molecule as set forth in SEQ ID NO:1 comprising a polynucleotide sequence encoding full length chicken type II collagen (CCII), or a fragment thereof in possession of the same biological functions as well as CCII encoded thereof. It also relates to a...

20060276388 - Hip/pap polypeptide compositions for use in liver regeneration and for the prevention of liver failure: This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytes, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding...

20060276382 - Materials and methods for treatment of allergic diseases: The present invention pertains to a method for treatment of allergic diseases by administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP, to a patient in need thereof. In another aspect, the present invention concerns an expression vector comprising a nucleic acid sequence encoding NHP. In...

20060276387 - Method of controlling transcription insulin gene: A method for promoting insulin gene transcription, which comprises the step of inhibiting binding of IPF1 and any one of proteins selected from the following group: (i) HNF3G, (ii) PHF1, and (iii) DLX4; and a method for screening a substance that promotes insulin gene transcription, which comprises the step of...

20060276394 - Methods and compositions for treating neurological disorders: The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In...

20060276393 - Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders: Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone,...

20060276399 - Peptide antagonists of zonulin and methods for use of the same: Peptide antagonists of zonulin are disclosed, as well as methods for the use of the same. The peptide antagonists bind to the zonula occludens receptor, yet do not physiologically modulate the opening of mammalian tight junctions....

20060276384 - Peptides and medicinal compositions containing the same: This invention provides a pharmaceutical composition comprising, as an active ingredient, a peptide derived from a PACAP or VIP peptide or a pharmaceutically acceptable salt thereof. This invention provides a PACAP/VIP derivative that can inhibit tautomerization in a solution and that can be applied to clinical applications over a long...

20060276395 - Pharmaceutical compositions of adiponectin variants and methods of storage: 1. A composition comprising an adiponectin variant at a concentration of at least 2.0 mg/mL, and a pharmaceutically acceptable carrier, wherein less than 20% of said adiponectin variant would aggregate after storage at 4° C. for one week in 10 mM PO4, 150 mM NaCl buffer....

20060276381 - Remedy for diabetes: The invention relates to a prophylactic or therapeutic for diabetes mellitus which comprises a growth-hormone secretagogue receptor (GHS-R) antagonist as an active ingredient, as well as a method of lowering the blood glucose level by administering a GHS-R antagonist. The invention further relates to a prophylactic or therapeutic which comprises...

20060276392 - Treatments employing neuronal exocytosis-inhibiting peptides: The peptide has a sequence of 3 to 30 adjacent aminoacids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain said peptide and optionally one or more peptides from the carboxyl end of SNAP-25. Said compositions are suitable for...

20060276391 - Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization: The present invention concerns the use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization. Partcularly, the above-mentioned diseases are (wet) age-related macular degeneration, (proliferative) diabetic retinopathy, neovascular glaucoma, retinal vein occlusion, or...

20060276386 - Use of substances inhibiting the association of said protein with ubiquitin c-terminal hydrolase for altering cellular responses to tgf-beta or bmp: Disclosed is a pharmaceutical composition for altering cellular responses to TGFβs and/or BMPs; the composition comprising a molecule which prevents, inhibits or reduces the association of a Smad protein with a UCH, in admixture with a physiologically acceptable carrier, excipient or diluent....

20060276400 - Modulation of cholesteryl ester transfer protein (cetp) activity: The present invention relates to autoantigenic vaccine peptides comprising a universal helper T cell epitope portion linked to a B cell epitope portion from the N-terminus of cholesteryl ester transfer protein (CETP). The vaccine peptides are useful for eliciting an autoimmune response in a vaccinated individual, i.e., raising antibodies against...

20060276401 - Polypeptides useful for appetite suppression: The present invention relates to polypeptides obtained from bear derivative isolate which are useful in suppressing appetite. The polypeptides of the present invention are most preferably between 12 and 13 amino acid residues in length and a mass of about 1249. The present invention also relates to a method of...

20060276403 - Agonist polypeptide of receptor for zot and zonulin: Agonist polypeptide of a receptor protein has been identified. The agonist can be used to facilitate drug and antigen absorption. Suitable routes of administration include oral, nasal, transdermal, and intravenous. Pharmaceutical formulations may comprise a therapeutic agent or an immunogenic agent in combination with the agonist polypeptide....

20060276402 - Synthetic peptide inhibitors of thrombin and thrombin activation of protease activated receptors 1 and 4: The invention relates to synthetic peptide analogs of D-Arg-Oic-Pro-Gly-Phe and methods of their use to inhibit human platelet aggregation, thrombosis and cell activation mediated by PAR1 and PAR4....

20060276409 - Antibacterial agents: R1 represents hydrogen, or C1-C6 alkyl or C1-C6 alkyl substituted by one or more halogen atoms; R2 represents a group R10—(X)n-(ALK)m- wherein R10 represents hydrogen, or a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, aryl, or heterocyclyl group, any of which may be unsubstituted or substituted by (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy,...

20060276408 - Beta-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins: There are disclosed β-sheet mimetics and methods relating to the same for imparting or stabilizing the β-sheet structure of a peptide, protein or molecule. In one aspect, β-sheet mimetics are disclosed having utility as protease inhibitors in general and, more specifically, as serine protease inhibitors such as thrombin, elastase and...

20060276404 - Medicaments and methods combining a hcv protease inhibitor and an akr competitor: Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of a hepatitis C virus (HCV) protease inhibitor and an aldo-keto reductase (AKR) competitor, for concurrent or consecutive administration in treating, preventing, or ameliorating one or more symptoms of HCV, treating disorders associated with HCV, or inhibiting cathepsin...

20060276405 - Methods for treating hepatitis c: Methods of treating hepatitis C are provided comprising using a therapeutically effective amount of at least one novel hepatitis C (“HCV”) protease inhibitor or, alternatively, at least one antiviral or immuno-modulating HCV agent, which is not an HCV protease inhibitor, for a first treatment period. Subsequently, a combination of the...

20060276406 - Methods of treating hepatitis c virus: Methods for preventing, ameliorating or treating one or more symptoms of Hepatitis C virus (HCV), modulating HCV protease activity and/or inhibiting cathepsin activity in a subject, wherein the methods comprise administering to a subject in need of such treatment a dosage formulation containing at least one compound of Formulae I-XXVI...

20060276407 - Methods of treating hepatitis c virus: Compositions and therapeutic combinations are provided including at least one compound selected from the group consisting of compounds of Formulae I to XXVI as defined herein as well as methods of treatment, prevention or amelioration of one or more symptoms of hepatitis C, treating disorders associated with HCV virus, modulating...

20060276410 - Compounds and methods for selective inhibition of dipeptidyl peptidase-iv: m

20060276412 - Methods and compositions for managing psychotic disorders: Compositions for treating psychotic disorders comprise a first ingredient and a second ingredient, wherein the first ingredient comprises at least one antipsychotic agent selected from the group consisting of ziprasidone, olanzapine and risperidone and the second ingredient comprises at least one anticonvulsant selected from the group consisting of zonisamide and...

20060276413 - New effector conjugates, methods for their preparation and their pharmaceutical use: Conjugates of epothilones and epothilone derivatives (as effectors) with suitable saccharides or saccharide derivatives (as recognition units) are described. Their production is carried out by the recognition units being reacted with suitable linkers, and the compounds that are produced are conjugated to the effectors. The pharmaceutical use of the conjugates...

20060276411 - Novel non-selective cation channel in neuronal cells and methods for treating brain swelling: The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is...

20060276415 - 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia: The invention discloses the use of sapogenin derivatives in the treatment of cognitive disfunction and similar conditions. Methods of treatment and pharmaceutical compositions are also disclosed...

20060276414 - Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain: The present invention relates to a method of treating or preventing musculoskeletal pain in a mammal receiving administration of an estrogen. suppressant selected from the group consisting of aromatase inhibitors, GnRH analogues, cyclo-oxy-genase 2 (COX-2) inhibitors, 17β-hydroxysteroid dehydrogenase type 1 inhibitors, progestogens, anti-estrogens and combinations thereof, said method comprising the...

20060276416 - Methods and compositions for treating flushing and drug induced weight gain: Provided herein are methods and compositions for treating and/or preventing flushing and/or weight gain. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary embodiments include methods and compositions for counteracting drug-induced weight gain and/or drug-induced flushing by administering a sirtuin-activating compound....

20060276417 - Treatment of inflammation: This invention relates to a method of treating inflammation comprising administering to a subject in need thereof a composition comprising the inventive compounds. Also disclosed is a method of treating inflammation where the subject is suffering from a rheumatic or inflammatory bowel disease....

20060276418 - Multidrug resistant anticancer anthracyclines: Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers....

20060276419 - Combined use of ribavirin and interferon beta in demyelinating diseases: u

20060276425 - Antisense oligomers and methods for inducing immune tolerance and immunosuppression: A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged,...

20060276424 - Compositions and methods for treatment of prostate and other cancers: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for...

20060276426 - Human peroxisome proliferator activated receptor gamma (ppargamma) gene regulatory sequences and uses therefor: This invention relates to the isolation and cloning of the promoter and other control regions of human PPARγ gene. It provides methods for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of the PPARγ gene. These agents interact...

20060276420 - Mesoderm and definitive endoderm cell populations: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy....

20060276427 - Regulation of endogenous gene expression in cells using zinc finger proteins: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins....

20060276422 - Rna interference mediated inhibition of b7-h1 gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating B7-H1 (also known as PD-L1) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of B7-H1 gene...

20060276421 - Staple type oligonucleotide and drug comprising the same: Conventional oligonucleotides are opened at both ends and thereby unstable. The stability of them against catabolic enzymes is increased by phosphorothioate modification, but such phosphorothioate causes toxicity. The present invention provides oligonucleotides and medicaments in which these problems are improved. That is, it provides a staple oligonucleotides and medicaments containing...

20060276423 - Survivin-directed rna interference-compositions and methods: The present invention is directed to compositions and methods for inhibiting the expression of survivin in cells expressing survivin. The invention is also directed to methods of treating conditions associated with elevated survivin, such as hyperproliferative disorders. More particularly, the invention is directed to inhibition of survivin expression using short...

20060276428 - A1 adenosine receptor agonists: e

20060276429 - Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation:

20060276430 - Formulations for mediating inflammation and for reducing blood cholesterol: The invention provides formulations for mediating inflammation and for lowering blood cholesterol. For example, inflammation of the intestine, retina or neural tissues, may be mediated. Further the formulations are effective in decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting...

20060276431 - Methods for treating severe acute respiratory syndrome: The invention provides methods for treating severe acute respiratory syndrome (SARS) with lipopolysaccharides....

20060276432 - Lipid-regulating agent and use thereof: The object of the present invention is to provide a lipid-regulating agent or a composition for regulating the amount of lipids comprising the agent. The present invention solves the above object by providing a lipid-regulating agent comprising a cyclic tetrasaccharide and/or its saccharide-derivative(s) and a composition for regulating the amount...

20060276434 - 3-carbonylaminothiophenes and their use as fungicides: The invention also relates to novel compounds of formula (I) where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by one to three groups R4; R1 is hydrogen, optionally substituted (C1-4)alkyl, formyl, optionally...

20060276433 - Hydrazone derivative: wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3...

20060276435 - Fibroblast activation protein inhibitor compounds and methods: Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro,...

20060276436 - Farnesyl dibenzodiazepinone formulation: The invention relates to pharmaceutical formulations comprising a farnesyl dibenzodiazepinone compound, or an analog, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable surfactant and having improved chemical and biological properties. Such a formulation is a ready-to-use solution suitable for parenteral or non-parenteral administration or a bulk...

20060276437 - Process for producing optically active dihydropyridinephosphonic ester: characterized by comprising: dissolving a racemate of the compound of formula (1) in a solvent to prepare a supersaturated solution; and adding crystal of either one optically active substance of the compound of formula (1) as a seed crystal in the supersaturated solution to allow crystal of the one optically...

20060276438 - Prevention and treatment of influenza with glutamine antagonist agents: A method of preventing or treating influenza or an influenza-related symptom in a subject by administering to the subject a glutamine antagonist agent is described....

20060276439 - Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium);...

20060276440 - Treatment of inflammatory disorders: Ring A is optionally substituted, contains zero, one, two, or three double bonds, and is optionally fused to an aliphatic, aryl or heteroaryl ring; X is an optionally substituted 1 to 3 carbon aliphatic chain that is optionally fused to a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring,...

20060276441 - Medicaments comprising steroids and a novel anticholinergic: n

20060276443 - 21-substituted progesterone derivatives as new antiprogestational agents: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group...

20060276442 - Methods of female sexual enhancement: A method of sexual enhancement in women includes the steps of identifying a woman requesting sexual enhancement, assuring that the woman's blood includes estradiol within a first predetermined range and testosterone within a second predetermined range, and thereafter administrating a drug selected from the group consisting of vardenafil hydrochloride and...

20060276444 - Porphyrin-polyamine conjugates for cancer therapy: Porphyrin-polyamine conjugate compounds are disclosed which have anticancer and antitumor effects. The porphyrin moiety selectively localizes in tumors, while the polyamine moiety serves as a cytotoxic agent. Methods of making and using the porphyrin-polyamine conjugate compounds are also disclosed....

20060276445 - Bicyclic 6-alkylidene-penems as class-d beta-lactamases inhibitors: r

20060276446 - Tricyclic 6-alkylidene-penems as class-d beta-lactamases inhibitors:

20060276448 - Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft...

20060276447 - Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain: d

20060276449 - 1,3-dihydro-2h-indol-2-one derivative: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to...

20060276450 - Isoquinoline potassium channel inhibitors: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like....

20060276451 - Preparation of hymenialdisine derivatives and use thereof: The synthesis and biological activity of indoloazepines and acid amine salts thereof which are structurally related to naturally-occurring hymenialdisine is disclosed. Naturally-occurring hymenialdisine obtained from the sponge is a potent inhibitor of production of cytokines interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α). The chemically-synthesized indoloazepines of the invention also inhibit...

20060276453 - Anti-cytokine heterocyclic compounds: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and...

20060276452 - Use of azetidinecarboxamide derivatives in therapy: The use of a compound of formula (1): wherein: R1 is aryl; R2 is H, alkyl or aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for the treatment of a disorder mediated by CB1 receptors....

20060276454 - Monoamine re-uptake inhibitors and methods relating thereto: wherein R1, R2, R3, R4, R5, R6, m, n, W, X, Y, and Z are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts, esters and solvates thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods...

20060276455 - Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia: The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia. The invention also relates to treatment of patients suffering from acute ischemic stroke, acute hemorrhagic stroke, subarachnoid hemorrhage, cerebral venous thrombosis or global cerebral ischemia...

20060276456 - Biphenyl vasopressin agonists: e

20060276457 - Piperazine-piperidines with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting...

20060276458 - Therapeutic compositions and methods: The present invention relates in general to therapeutic compositions and methods of use. In preferred embodiments, the invention relates to the field of eye health. In some embodiments, the invention relates to the prevention and treatment of macular degeneration by administering compounds disclosed herein. In some embodiments, the invention relates...

20060276459 - Methods of treating cell proliferative disorders: The present disclosure provides methods for the treatment of cell proliferative disorders by administration of a Syk kinase or Syk/Flt-3 kinase inhibitor. Cell proliferative disorders treatable by the methods include, hematopoietic neoplasms and virally associated tumors. The compounds are also directed to therapeutic or prophylactic inhibition of tumor metastasis....

20060276460 - Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns: This invention relates to a new use of piperazinephenothiazine derivatives and their pharmaceutically acceptable salts or esters in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on CNS and/or PNS. The piperazine phenothiazine derivatives are selected from compounds of formula (I) wherein A represents a straight or branched...

20060276461 - Prostaglandin analogs: i

20060276462 - Method of treating cognitive decline due to sleep deprivation and stress: This invention relates to methods of use for AMPA receptor potentiator compounds and pharmaceutical compositions in the prevention and treatment of cognitive impairment as a result of acute or chronic sleep deprivation, including enhancement of receptor functioning at synapses in brain networks responsible for higher order behaviors. A still further...

20060276463 - Pure levofloxacin hemihydrate and processes for preparation thereof: The invention relates to pure levofloxacin hemihydrate and a process for preparing pure levofloxacin hemihydrate. The invention also relates to pharmaceutical compositions that include the pure levofloxacin hemihydrate and use of said compositions for treating a patient in need of an antimicrobial therapy....

20060276465 - 1,2-di(cyclic) substituted benzene compounds: wherein R10 represents 5- to 10-membered cycloalkyl etc. optionally substituted with hydroxyl etc., R30, R31 and R32 may be the same or different and each represents hydrogen etc., R40 represents C1-10 alkyl etc. optionally substituted with hydroxyl etc., n represents an integer of 0, 1 or 2, X1 represents CH...

20060276466 - Bicyclic heterocycles as hiv integrase inhibitors: The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV....

20060276464 - Diarylsulfone sulfonamides and use thereof: e

20060276467 - Sodium channel modulators: The invention provides sodium channel modulating compounds which are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. The invention also provides pharmaceutical compositions comprising a compound of the present invention, as well as therapeutic methods comprising administering such a compound or salt to...

20060276469 - 3-methanesulfonylquinolines as gabab enhancers: e

20060276468 - Wood preservative formulations comprising imazalil: The invention provides a wood preservative composition comprising a synergistic combination of imazalil or imazalil sulfate and one or more co-biocides. Examples of such co-biocides include triclosan, fenarimol, dichlorophen and chlorothalonil. The efficacy of potential wood preservative compositions can be tested by a simple test provided herein....

20060276470 - Inhibition of phsphoinostide 3-dinase beta: The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel...

20060276471 - Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer....

20060276472 - Pharmaceutical composition intended for the prevention or for the treatment of cerebral oedemas: r

20060276474 - Novel carboxylic acid derivatives, their preparation and use:

20060276473 - Use and administration of bacterial efflux pump inhibitors: This invention provides for efflux pump inhibitors to be co-administered with antimicrobial agents for the treatment of infections caused by drug resistant pathogens, novel efflux pump inhibitors, combined dosage forms of efflux pump inhibitors with an antimicrobial, and novel medical methods....

20060276475 - Triazolotriazines and pyrazolotriazines and methods of making and using the same: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I: (I)...

20060276476 - Carboxylic acid derivatives that inhibit the binding of integrins to their receptors: A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control...

20060276477 - Treatment method for anemia: The present invention relates to improved methods for treating anemia. Methods and compounds useful for treating anemia, wherein the anemia treatment is associated with a lower risk of thrombosis or hypertension compared to that observed with rhEPO therapy, are provided....

20060276478 - Pyrazolopyrimidines: e

20060276479 - Heterocyclic substituted piperazines with cxcr3 antagonist activity: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting...

20060276480 - Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft...

20060276481 - Antidepressant arylpiperazine derivatives of heterocycle-fused benzodioxans: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating...

20060276482 - Benzoimidazolone-carboxamide compounds as 5-ht4 receptors agonists: The invention provides novel benzoimidazolone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds....

20060276483 - Aerosolized fluoroquinolones and uses thereof: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures...

20060276484 - Use of selective dopamine d4 receptor agonists for treating sexual dysfunction: The present invention relates to the use of selective dopamine D4 receptor agonists and to compositions containing selective dopamine D4 receptor agonists for the treatment of sexual dysfunction....

20060276485 - Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators: The present invention relates to novel substituted piperidine and piperazine derivatives as melanocortin-4 receptor (MC-4R) modulators. MC-4R agonists of the invention can be used for the treatment of disorders and diseases such as obesity, diabetes, and sexual dysfunction, whereas the MC-4R antagonists are useful for the treatment of disorders and...

20060276486 - Lklf/klf2 gene expression promoter: Expression of LKLF/KLF2 gene can be promoted by administering, as an active ingredient, an effective amount of a substance capable of inhibiting the mevalonic acid metabolic pathway....

20060276488 - N-heterocyclic inhibitors of tnf-alpha expression: p

20060276487 - New compounds useful for dpp-iv enzyme inhibition: The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX)....

20060276489 - Inhibitors of tubulin polymerization: The invention relates to the inhibition of tubulin polymerization. The invention provides compounds and methods for inhibiting tubulin polymerization. The invention also provides compositions and methods for treating cell proliferative diseases and conditions....

20060276490 - Thiopyrimidine and isothiazolopyrimidine kinase inhibitors: e

20060276491 - Therapeutic compounds: The invention provides novel JAK-3 inhibitors that are useful for treating leukemia and lymphoma. The compounds are also useful to treat or prevent skin cancer, as well as sunburn and UVB-induced skin inflammation. In addition, the compounds of the present invention prevent the immunosuppressive effects of UVB radiation, and are...

20060276493 - Alpha- and beta-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors: α- and β-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as-inhibitors of HIV protease....

20060276492 - Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane: A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A...

20060276494 - Novel sulfonamides as l-cpt1 inhibitors: m

20060276495 - Treatment methods of nasal congestion and nasal obstruction: The use of desloratadine and/or other antihistamines for treating and/or preventing severe nasal congestion and/or nasal blockage associated with allergic and inflammatory conditions of the upper and lower airway passages in a human....

20060276496 - Anti-cytokine heterocyclic compounds: Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and...

20060276497 - Novel multicyclic compounds and the use thereof: The present invention is directed to novel multicyclic molecules that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of PARP, VEGFR2, and MLK3 enzymes, including, for example, neurodegenerative diseases, inflammation, ischemia, and cancer....

20060276498 - 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective...

20060276500 - Compositions and methods for treating nocturnal acid breakthrough and other acid related disorders: The present invention relates to, inter alia, pharmaceutical compositions comprising an acid labile proton pump inhibitor and a buffering agent; to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders....

20060276499 - Imidazopyridine intermediates: The invention relates to compounds of the formula (I), in which the substituents and symbols have the meanings indicated in the description. The compounds are valuable intermediates for the preparation of pharmaceutical active compounds....

20060276501 - Solid compositions for treating middle-of-the-night insomnia: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof....

20060276502 - Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53.: The present invention relates to the use of 1-azabicyclo[2.2.2]octanes, capable of transferring wild type p53 from an inactive and non-functional conformation into an active conformation, for the preparation of a pharmaceutical compositions for use in treating medical compositions wherein wt p53 exists in an inactive state defined herein, especially malignant...

20060276503 - Novel process salts compositions and use: The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy....

20060276504 - Ophthalmic compositions for treating ocular hypertension: This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective...

20060276505 - Acylhydrazine p2x7 antagonists and uses thereof: i

20060276506 - Compounds for the treatment of inflammatory disorders:

20060276508 - Amide derivatives as somatostatin receptor 5 antagonists: wherein R1 to R5, R5′ and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated...

20060276507 - Hydroxamate sulfonamides as cd23 shedding inhibitors: A class of piperidine and related heterocyclic derivatives, C-substituted by a substituted aryl or heteroaryl moiety, and N-substituted by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are...

20060276509 - Tripeptidyl peptidase inhibitors: wherein n is an integer 0 or 1; X represents O; S; or —(CR4R5)m— wherein m is an integer 1 or 2; R4 and R5 are each independently from each other hydrogen or C1-4alkyl; R1 is C1-6alkylcarbonyl optionally substituted with hydroxy; C1-6alkyloxycarbonyl; aminoC1-6alkylcarbonyl wherein the C1-6alkyl group is optionally substituted...

20060276510 - Dihydropyridine compounds and compositions for headaches: The invention provides methods for treating and/or preventing headaches by administering to patients therapeutically effective amounts of 1,2-dihydropyridine compounds, and, optionally, cholinesterase inhibitors and/or anti-migraine agents. The headaches may be primary headaches, such as migraines, or secondary headaches. The invention also provides combinations, commercial packages, and pharmaceutical compositions comprising therapeutically...

20060276511 - Inhibitors of hcv replication: e

20060276512 - Fumagillol derivatives and preparing method thereof: The disclosure relates to a fumagillol compound which can be usefully used not only as an angiogenesis inhibiting agent showing a superior angiogenesis inhibitory effect with less toxicity, but also as a cancer metastasis inhibitor and a therapeutic agent against cancer and other various inflammatory diseases such as rheumatic disease,...

20060276513 - Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester: Disclosed are polymorphs of the active substance 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2 -yl-amino]-propionic acid ethyl ester, the preparation thereof and the use thereof as pharmaceutical compositions....

20060276515 - Soluble epoxide hydrolase inhibitors and methods of using same: Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same....

20060276514 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a substituted pyrrole moiety. The present invention is also related to the pharmaceutically acceptable...

20060276516 - Nicotinamide derivatives useful as p38 inhibitors: e

20060276518 - Aryl and heteroaryl compounds and methods to modulate coagulation: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway...

20060276517 - Non-systemic control of parasites: Use of agonists and antagonists of the nicotinergic acetylcholine receptors of insects for the non-systemic control of parasitic insects, such as fleas, lice and flies, on humans and on animals....

20060276519 - Thiazole derivatives for treating ppar related disorders: The present invention provides combinations of compounds of formula (I) and other therapeutic agents for the treatment of PPAR related diseases....

20060276520 - Rhodanine derivatives and pharmaceutical compositions containing them: This invention describes rhodanine derivatives and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating cell proliferative diseases such as...

20060276521 - Thiazole derivatives: A compound of the formula (I): R1—NH—X—Y-Z (I) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema, which method includes...

20060276522 - Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors: A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases. (I)...

20060276523 - Nitoroxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases: n

20060276524 - 2,5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12:

20060276526 - Crystalline form of telmisartan sodium: The invention relates to a crystalline sodium salt of 4′-[2-n-propyl-4-methyl-6-(1-methyl-benzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid (INN: telmisartan), processes for preparing it and the use thereof for preparing a pharmaceutical composition....

20060276525 - Processes of preparing highly pure telmisartan form a, suitable for pharmaceutical compositions: Processes are disclosed for preparing Telmisartan form A, which is free-flowing and which does not contain electrostatic charge and is thus industrially process-able. The free-flowing Telmisartan form A is prepared by crystallization from a polar organic solvent e.g., DMSO, DMF, DMA, NMP, or water and is suitable for use in...

20060276527 - Combination therapies for the treatment of cancer: Lonidamine or a lonidamine analog is administered with one or more additional anti-cancer agents or surgery or radiation to treat cancer or is administered alone or in combination to treat cancer, optionally in a sustained release formulation, and improve patient outcome....

20060276528 - Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents: The present invention is directed to novel benzo-fused heteroaryl sulfamide derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders. The present invention is further directed to a crystalline form of N-(benzo[b]thien-3-ylmethyl)-sulfamide and a process for its preparation....

20060276529 - Use of plasma membrane calcium atpase (pmca) inhibitors for inhibiting sperm mobility: The invention relates to the use of plasma membrane calcium ATPase (PMCA) inhibitors for inhibiting sperm mobility to achieve a contraceptive effect. The invention further relates to contraceptive agents comprising one or more PMCA inhibitors....

20060276530 - Ampo spin traps: e

20060276531 - Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia: The present invention provides an agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia, comprising, as an active ingredient, a compound having a slowly-inactivating A-type K+ channel opening activity or a pharmaceutically acceptable salt thereof, and a method for screening agents for the treatment of bladder...

20060276532 - Ampa receptor potentiators: e

20060276533 - Compounds and methods for the treatment or prevention of flavivirus infections:

20060276534 - Methods of decreasing calcification: The present invention relates to methods of treating vascular calcification in subjects using calcimimetics....

20060276535 - Novel compounds for treatment of cardiac arrhythmia and methods of use: The subject invention provides novel compounds for treatment of cardiac arrhythmia and methods of use....

20060276536 - Cancer treatment using curcumin derivatives: Cancer or a precancerous condition is treated by administering a curcumin derivative to a subject....

20060276537 - Use of ladostigil for the treatment of multiple sclerosis: Disclosed are methods for the treatment of a form of multiple sclerosis comprising administering an amount of R(+)-6-(N-methyl, N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof....

20060276538 - Metal carnitine chelates: Metal carnitine chelates comprising carnitine chelated to a nutritionally relevant metal can be used for general nutrition as well as well as to treat a variety of health related problems and symptoms. For example, metal carnitine chelates can be used to maintain good cardiovascular health, increase male fertility, enhance weight...

20060276540 - Selective androgen receptor modulators: The present invention relates to androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity, which are nonsteroidal ligands for the androgen receptor. The selective androgen receptor modulators (SARM) are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen...

20060276539 - Treating androgen decline in aging male (adam)- associated conditions with sarms: This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory...

20060276541 - Fruit, vegetable, and seed disinfectants: Antimicrobial formulations are described that can be used to reduce levels of microbes on the surfaces of plants and plant parts....

20060276542 - Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or, more compounds with smooth muscle modulatory effects to treat functional bowel disorders in patients in need of treatment. According to the present invention,...

20060276543 - Crystalline forms of pregabalin: Crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.8, 18.4, 19.2, 20.7, and 23.7° 2θ±0.2° 2θ, methods for its preparation, its pharmaceutical compositions thereof, and methods for the preparation of crystalline form of Pregabalin characterized by X-ray powder diffraction peaks at about 5.7, 15.4, 17.2, 18.2,...

20060276544 - Pregabalin free of isobutylglutaric acid and a process for preparation thereof: A Pregabalin having a low level of 3-isobutylglutaric acid is provided....

20060276545 - Polyhydroxy phenols and their use in binding p-selectin: Polyhydroxy phenols, which are non-peptidic mimetics of galloyl peptides, and a process for the preparation of gallic acid derivatives using a gallic-acid providing moiety are provided as well as polyhydroxy phenol-containing pharmaceutical and nutraceutical compositions. The use of polyhydroxy phenols as a medicament and especially for the manufacture of a...

20060276546 - Uses of prostacyclin analogs: The present invention provides a method for preventing or reducing the risk of cancer or the progression of premalignant dysplasia in a subject having a higher risk factor by administering a therapeutically effective amount of prostacyclin analog....

20060276547 - Methods of treating cancer with hdac inhibitors: The present invention relates to methods of treating cancers, e.g., lymphoma. More specifically, the present invention relates to methods of treating diffuse large B-cell lymphoma (DLBCL), by administration of pharmaceutical compositions comprising HDAC inhibitors, e.g., suberoylanilide hydroxamic acid (SAHA). The oral formulations of the pharmaceutical compositions have favorable pharmacokinetic profiles...

20060276548 - Inhibitors of endo-exonuclease activity for treating cancer: The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in...

20060276549 - Combination and use of drugs: The present invention is directed to preferred pharmaceutical compositions comprising sibutramine and rimonabant and use of sibutramine and rimonabant to treat obesity and obesity related disorders in a patient....

20060276550 - Topical compositions of ketamine and butamben and methods of their use: Disclosed are pharmaceutical compositions comprising ketamine and butamben. The compositions are useful in the treatment of pain....

20060276551 - Exo-s-mecamylamine formulation and use in treatment: A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine...

20060276552 - Methods and devices for non-invasive cerebral and systemic cooling: A method for cerebral and systemic cooling by providing a nebulized liquid having a boiling point of 38-300° C. The nebulized liquid is delivered as a mist or a spray via the nasal and/or oral cavities of a patient. The mist causes cooling by direct heat transfer through the nasopharynx...